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Exosomes are small lipid membrane bound vesicles formed as part of the 
endosomal pathway and released into the extracellular space following 
fusion of late endosomes with the plasma membrane.  Exosomes have been 
shown to have a variety of biological roles and may represent a novel source 
of disease biomarkers.   
 
The objectives of this project were to develop a panel of techniques for 
identifying exosomes in human urine then establish an in vitro model to 
determine whether exosomes change with cellular activation. We then used 
the techniques developed with human urine to determine whether human 
cerebrospinal fluid (CSF) contains exosomes and applied a mass 
spectrometry based approach to characterise the exosomal proteome.  
 
We used western blot for three exosomal markers (tsg101, CD24 and flotillin-
1), isopycnic centrifugation on a sucrose density gradient and direct 
visualisation using transmission electron microscopy (TEM) to verify the 
presence of exosomes.  Using GeLC-MS/MS, 88 proteins were identified in 
the urinary exosomes.  Several of these proteins could be linked to diseases 
and specific sections of the nephron.   
 
A murine cortical collecting duct cell line was used to model exosome release 
into the urine.  Firstly, exosome release was verified using the approach 
developed in the urine.  Stimulation of the cells with desmopressin caused an 
increase in the presence of aquaporin 2 in the exosomes.  This increase 
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reflected a similar change in the cells and occurred over a similar time 
course.  This supports the hypothesis that the exosomes reflect the state of 
the kidney cells.  In contrast, stimulation with cisplatin did not alter the 
presence of Fetuin-A, a proposed biomarker of cisplatin-induced acute 
kidney injury, in exosomes and this was consistent with no change in Fetuin-
A expression in the cells. 
 
The released exosomes may act as mediators of communication to other cells.  
Following incubation of mCCD cells with AQP2 containing exosomes AQP2 
in the cell lysate was increased indicating interaction between the cells and 
exosomes and potentially internalisation. 
 
Exosomes have been shown to be released by neuronal cells in vitro. We 
identified exosomes in the CSF of humans using western blot for known 
exosomal markers, density determination and direct visualisation with TEM 
and Immuno-TEM using an antibody specific for the exosomal marker 
flotillin-1.  Label-free quantitative mass spectrometry was used to compare 
multiple CSF samples.  On a whole protein analysis 86% of the proteins 
identified varied by less than 2-fold in comparison to the average across 
samples.  On a tryptic peptide analysis 75% of the peptides identified varied 
by less than 2-fold in comparison with the average across samples.   
 
We have demonstrated exosomes are present in urine, CSF and mCCD cell 
conditioned media.  In the mCCD cell derived exosomes we have 
demonstrated that following stimulation the proteome of the exosomes 
changes and that this change reflects the change seen in the cells.  For the 
urinary and CSF exosomes we have characterised their proteomes using 
  vi    
GeLC-MS/MS.  These findings are consistent with the hypothesis that 
exosomes are a rich source of information, including biomarkers, on their 
cells of origin. 
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1.1. Exosomes 
 
Cells release various types of membrane vesicles under physiological and 
pathological conditions (Figure 1.1).  Although these vesicles vary widely in 
origin they share several common traits.  They are all approximately 
spherical, contain soluble proteins in their lumen and are bounded by a lipid 
bilayer similar to other membranes in the cell.  This lipid bilayer displays the 
luminal surface of the membrane from which the vesicle formed.  For 
example, a vesicle formed from the plasma membrane will outwardly 
display the extracellular surface of the plasma membrane.  This is in contrast 
to intracellular vesicles which enclose their luminal surface [1].  The released 
membrane vesicles vary in site of origin, size, density, and protein and lipid 
content (Table 1.1).  This heterogeneity is not always clear in published 
articles where the terminology for different particles may be confused [2].  
The term microparticle is often used to describe membrane vesicles which 
have not been thoroughly characterised or samples which may be a mixture 
of vesicles of different types, such as might be obtained from complex 


















Figure 1.1  The cell releases a variety of different membrane vesicles.   
The formation and release of vesicles occurs at two principal sites; the plasma 
membrane and intracellularly.  The largest spectrum of vesicles is released from the 
plasma membrane ranging from the larger microvesicles and apoptotic vesicles to 
the smaller ectosomes and membrane particles.  This method of release can also be 
utilised by enveloped viruses to mediate their release from cells.  In contrast 
exosomes form intracellularly within late endosomes and only exit the cell following 
fusion of the late endosome with the plasma membrane. 
 
 
   
 























20-50 1.10 Irregular Do not contain lipid 
rafts 
TNFRI ? [4] 



























50-500 1.18-1.28 Heterogeneous ? Histones ? [8] 
Table 1.1  Characteristics of the different types of membrane derived vesicles.
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1.1.1. Exosomal Biogenesis 
Exosomes are formed as part of the endosomal pathway within eukaryotic 
cells.  Invagination of the plasma membrane forms early endosomes which 
mature into late endosomes.  During the maturation process the limiting 
membrane of the early endosomes undergoes invagination forming small 
vesicles in the lumen of the endosome.  In the classical endosomal pathway 
the late endosomes fuse with the lysosomes and the contained vesicles and 
proteins are degraded. However, in 1987, it was demonstrated that the late 
endosomes can also fuse with the plasma membrane which releases the 
contents of the late endosome into the extracellular space [3].  The released 
vesicles are termed exosomes.  
 
The invagination of the limiting membrane of the endosome is a multi-step 
process orchestrated by the Endosomal Sorting Complex Required for 
Transport (ESCRT) complexes (Figure 1.2). The protein hepatocyte growth 
factor-regulated tyrosine kinase Substrate (HRS) is targeted to endosomes via 
a FYVE domain (a four amino acid sequence of phenylalanine, tyrosine, 
valine and glutamic acid), which binds phosphatidylinositol 3-phosphate.  
Once bound, HRS which together with Signal Transducing Adaptor 
Molecule (STAM)-1 and STAM2 are often termed ESCRT-0, interacts with 
Tumor Susceptibility Gene (TSG)-101 which is a constituent of the ESCRT-I 
complex.  The ESCRT-I complex then recruits ESCRT-II which causes the 
assembly of the ESCRT-III complex.  From small structurally related 
monomers the large polymeric ESCRT-III complex assembles.   The final step 
which forms the intralumenal vesicles is poorly understood, but the 
prevalent opinion is that it involves the disintegration of the ESCRT-III 
complex by the action of the Charged MVB Protein subunit (CHMP)-4[9].  








Figure 1.2  Schematic representation of the ESCRT complexes.   
ESCRT-I and ESCRT-II exist as stable tetrameric complexes and are recruited in turn 
to the endosomal membrane following the interaction of the ESCRT-0 complex with 
phosphatidylinositol 3-phosphate in the membrane.  Finally the components of the 
ESCRT-III complex, which exists as soluble monomers, assemble on the membrane 
and mediate membrane scission. 
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In addition to forming the intralumenal vesicles, the ESCRT complexes also 
mediate the inclusion of monoubiquitinated proteins into the intralumenal 
vesicles of late endosomes.  The complexes ESCRT-0, -I and -II all contain 
ubiquitin binding domains which act to mediate the inclusion of 
monoubiquitinated cargo proteins into the endosomal pathway [9].  The 
STAM proteins present in the ESCRT-0 complex also recruit ubiquitin ligases 
and deubiquitinating enzymes which it is hypothesised release the ubiquitin 
from cargo proteins before they are encapsulated in the intralumenal vesicles 
[9].  Little is known about this process and, although the presence of 
deubiquitinating enzymes suggests ubiquitin is removed, many proteins in 
released exosomes are still associated with ubiquitin [10].  No ESCRT 
independent pathway for the inclusion of monoubiquitinated proteins in to 
intralumenal vesicles has been identified but monoubiquitination is not the 
only mechanism by which proteins are included in the intralumenal 
vesicles[11, 12].  Exosomes contain tetraspanins [13] and GPI-linked proteins 
which are known to be associated with lipid rafts [14].  Cholesterol and 
sphingolipids are enriched in both lipid rafts and exosomes suggesting that 
formation of intralumenal vesicles is enhanced at lipid rafts [1, 11].  In 
addition to their role in protein sorting into the intralumenal vesicles lipids 
may also be able to mediate the inwards invagination of the endosomal 
membrane which is required for vesicle formation.  Lyso-bisphosphatidic 
acid (LBPA) has an unusual inverted cone shape which may favour inward 
invagination [15, 16].  Although present in mammalian cells LBPA is absent 
in yeast providing one possible explanation why ESCRT complexes are 
essential in yeast but not in mammalian cells for exosome formation [17]. 
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1.1.2. Biological Activity 
Since first being observed, evidence has accumulated that exosomes are more 
than inert particles to be expelled from the body and have a variety of 
biological roles mediated by their proteome (Table 1.2). In addition to release 
during reticulocyte maturation exosomes are also involved in morphogen 
signalling and a variety of immunological activities [18-20].  Argosomes, 
which appear identical to exosomes, have been described [21, 22] as a 
mechanism for the dispersal of morphogens, specifically Wingless in 
Drosophila, and the creation of the morphogen gradient.  Exosomes have both 
immuno-stimulatory and immuno-inhibitory activities depending on the 
context.  B cells which have been transformed with Epstein-Barr virus release 
exosomes which can activate CD4+ T cells.  This activation is antigen specific 
[23].  Dendritic cells which have been pulsed with peptides from tumours 
release exosomes which support tumour rejection.  Again, this activity is 
antigen specific [24, 25].  Exosomes released from melanoma [26], prostate 
[27] and mammary [28] tumour cells have been shown to mediate 
lymphocyte apoptosis and may be involved in tumour immune evasion.  
Intestinal epithelial cells release exosomes which may mediate antigen 
presentation in the mucosal and systemic immune system and be involved in 
tolerance [29].  During pregnancy exosomes of placental origin are present in 
the maternal circulation and may be involved in the deletion of reactive 
lymphocytes [30, 31].  Exosomes may also be involved in the progression of 
neurological disease.  β-amyloid peptide which is involved in the 
pathogenesis of Alzheimer’s disease is released from cells in association with 
exosomes [32].  Prion infectivity is released from neuroblastoma cells in 
association with exosomes in vitro [33-35] and in vivo is present in exosomes 
purified from the cerebrospinal fluid of sheep [36]. 
   
Cell of release Mechanism Target cell Action Reference 
Reticulocyte Exosome carries 
transferring receptor 




Ere reported Drosophila 




Developing tissues Establishes 
morphogen gradient 
[21, 22] 
B cells Antigen presentation T cells T cell activation [23] 
Dendritic cells Antigen presentation Tumour cells Support tumour 
rejection 
[24, 25] 
Tumour cells Exosome carries FasL Lymphocytes Lymphocyte apoptosis 





Antigen presentation CD4+ T cells Tolerance [29] 
Placental cells Exosome carries FasL T cells Deletion of reactive 
lymphocytes 
[30, 31] 
Neuroblastoma cells Exosome carries β-
Amyloid 
Neuroblastoma cells Plaque formation in 
Alzheimer’s disease 
[32] 
Neuroblastoma cells Exosome caries the 
prion protein 
Neuroblastoma cells Progression of TSEs [33-35] 
Table 1.2  Summary of the protein mediated biological roles for exosomes.
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1.1.3. Exosome Purification 
Since first being observed during reticulocyte maturation it has been found 
that exosomes are released from a wide variety of cells for example,  T and B 
[13, 23] lymphocytes, dendritic cells [37], mast cells [38], intestinal epithelial 
cells [29], platelets and neuroblastoma cells[35].  Although the number 
released varies, it appears that exosomes are released by all cell types in vitro.  
In vivo exosomes can be isolated from plasma [39], urine [10, 40], mouse and 
sheep cerebrospinal fluid [36, 41], human ascites fluid [42, 43], human and 
mouse amniotic fluid [40], human saliva [44] and mouse bronchoalveolar 
fluid [45]. 
 
In comparison to soluble proteins exosomes are present at a relatively low 
concentration in biofluids.  For their study it is necessary to concentrate them 
preferentially compared with the soluble proteome.  In the literature two 
methods have been used to achieve this; ultracentrifugation and molecular 
filtration [46].  Ultracentrifugation is by far the most common technique used 
but the necessary equipment may not be available in all laboratories and the 
process is time consuming.  Molecular filtration has been used for the 
purification of exosomes only more recently.  This approach holds promise 
as the necessary equipment is more commonly available and the process is 
relatively quick.  Differences in the purified sample in comparison to 
ultracentrifugation have not yet been studied.  Currently it is unclear how 
the samples prepared by ultracentrifugation and molecular filtration may 
differ, although some evidence is now emerging [47].  For all samples in this 
thesis ultracentrifugation has been used for isolation to facilitate direct 
comparisons with prior studies. 
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Although exosomes were first described in 1985 [48] there has been no 
consensus on the optimum purification strategy.  The centrifugal force and 
the period of centrifugation differ widely between groups.  The time 
required to pellet the exosomes is determined by the centrifugal force and 
the radius of the rotor used.  These two properties are summarised by the k-
factor.  A lower k-factor suggests less time is required to sediment a particle.  
When sufficient information is reported to calculate the k-factor used in 
previous publications on exosomes it has varied from 356 [40] to 82 [10].   
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1.2. Proteomics 
Since the success of the human genome project there has been a growing 
focus within the life sciences on studies at the system level.  The goal has 
become the identification of the individual components that make up a 
system and their subsequent quantification under different conditions.  
Proteomics is the large scale determination of cellular function at the protein 
level.  The completion of the human genome has been highly advantageous 
to the field of proteomics offering a sequence-based framework for data 
analysis [49]. Whereas the genome of an organism is constant throughout its 
existence the proteome is dynamic, as is the transcriptome, and varies 
between time-points, tissues, and environmental conditions. Importantly, 
although related, changes in the transcriptome do not always reflect changes 
in the proteome.  As a result, to understand the proteome we must study it 
directly [50-52]. 
 
Proteomic studies can be broken down into two principle types; expression 
proteomics which focuses on analysing and quantifying the expression or 
more specifically concentration of expressed proteins within a cell, tissue or 
biofluid, and cell-map proteomics which focuses on understanding the 
interactions between proteins in the cellular context [53].  Recently the latter 
is increasingly referred to as interactomics [54].  In both cases the focus is on 
the identification and quantification of many proteins, or identification of 
many protein interactions, simultaneously. 
 
The identification of many proteins in a complex mixture is possible using 
two main techniques.  With the development of soft ionisation techniques 
mass spectrometry (MS), coupled with a variety of separation techniques, has 
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emerged as the leading approach for proteomics [54, 55].  MS based 
techniques require no prior knowledge of the proteins being studied and, as 
such, are ideally suited to discovery studies. 
 
Protein arrays which offer a potential alternative for studying well 
characterised proteomes.  Protein arrays, or protein microarrays, are 
conceptually similar to microarrays for transcriptomics.  Instead of having a 
plate displaying a variety of short DNA fragments to which complementary 
cDNA molecules bind, a variety of capture probes are attached to a plate 
which then bind their complementary proteins [56].  For each protein to be 
assayed a capture probe, usually an antibody, must be developed which is 
highly sensitive, so that the target can be detected even at low 
concentrations, and highly specific, so that confidence can be maintained 
even in complex protein mixtures where cross-reactivity is a potential 
concern.  For these reasons the creation of a protein assay capable of 
screening a sample for a large number of different proteins is expensive and 
technically challenging.  Furthermore, good knowledge of the proteome 
being studied is a prerequisite for the development of protein arrays and 
they are better suited to validation studies rather than discovery studies.  As 
no protein array currently exists for the exosomal proteome our focus is 
solely on mass spectrometry-based proteomics. 
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1.3. Mass Spectrometry Based Proteomics 
The proteomic analysis itself can broadly be broken down into three steps; 
separation, ionisation and mass determination.  With the exception of Surface 
Enhanced Laser Desorption Ionisation (SELDI) and Capillary 
Electrophoresis-Mass Spectrometry (CE-MS) - for which the aim is 
quantification without identification of the ions detected - the majority of 
proteome analyses include a fourth step; protein fragmentation by the action 
of an endopeptidase, usually trypsin.  The identity of an ion cannot be 
accurately determined from the weight alone due to errors in mass 
determination, translational modifications and the complexity of the 
proteomes studied.  Fragmentation of the protein and subsequent detection 
of several peptides provides greater confidence in the identity assigned [57].  
For each step a variety of techniques have been developed, each with 
advantages and disadvantages.  Although certain techniques are frequently 
used together (Table 1.3) with just a few exceptions they are interchangeable.  
It is important to use the combination of techniques which best match the 
characteristics of the experimental samples and the objectives of the study. 
   
Technique SELDI CE-MS 2D PAGE MALDI GeLC-MS/MS LC-MS/MS 
Separation 
method #1 
Proteins in a sample 
selectively bind to 




Isoelectric focusing of 
intact proteins 
SDS-PAGE of intact 
proteins 
Reverse phase liquid 
chromatography of 
tryptic peptides Separation 
method #2 
SDS-PAGE of intact 
proteins 
Reverse phase liquid 
chromatography of 
tryptic peptides 
Digestion? No No Yes Yes Yes 
Mass 
spectrometer 
Time of flight Time of flight Time of flight Various though 
quadrupole and ion 
traps are popular 
Various though 
quadrupole and ion 




Protein identification is 
difficult.  Focus is on 
quantitation of ions. 
Protein identification is 
difficult.  Focus is on 
quantitation of ions. 
Mass fingerprinting or 
tandem mass spectra 
Tandem mass spectra Tandem mass spectra 
Advantages Can be automated 
High throughput 
Can be automated 
High throughput 







Disadvantages Protein identification 
Variability 
Protein identification 
Limited to <10 kDa 
Labour intensive 
Resolution of small 
and membrane 
proteins 
Not automatable High abundance 
proteins mask proteins 
of lower abundance 
Table 1.3  Summary of popular combinations of separation and detection methods used in mass spectrometry.
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1.3.1. Separation 
Due to the complexity of the proteome it is vital to separate it into fractions 
prior to analysis.  This can be achieved ‘online’ with the mass spectrometer 
where the eluent from separation is fed directly into the mass spectrometer 
or ‘offline’ where the separation technique is not connected directly to the 
mass spectrometer. 
 
When protein fragmentation by tryptic digestion is used, separation can 
occur at two distinct steps.  Intact proteins can be separated prior to 
digestion or the peptides resulting from digestion can be separated prior to 
analysis on the mass spectrometer.  Separation prior to and after digestion is 
not mutually exclusive with many studies combining both. 
 
Two dimensional gel electrophoresis was first described in 1975 [58] and, 
despite alternative techniques being developed since, remains a mainstay of 
proteomic research.  In 2D gel electrophoresis proteins are resolved in the 
first dimension by their isoelectric point in an electric field and then by their 
molecular weight using denaturing polyacrylamide gel electrophoresis in the 
second dimension.  Proteins, resolved as spots on the gel, can be excised for 
identification.   
 
2-D gels have several drawbacks.  They perform poorly at resolving low 
molecular weight proteins, a particular problem for soluble urinary 
proteomics, and membrane proteins, a particular problem for exosome 
proteomics.  Differences between gels also make comparisons difficult 
although the emergence of Difference In Gel Electrophoresis (DIGE) has 
minimised the difficulties with comparing result sets [59]. 
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Liquid chromatography (LC) is the most commonly used ‘online’ 
fractionation method.  There is a limit on the size of proteins which can be 
separated by liquid chromatography and so it is usually used following 
tryptic digestion.  Typically reversed phase liquid chromatography is used in 
which the mobile phase is a polar aqueous solution and the stationary phase 
is hydrophobic, typically C18.  Elution of peptides is achieved by a 
water/acetonitrile gradient with an increasing acetonitrile concentration 
liberating increasingly hydrophobic peptides from the stationary phase.  
During this thesis LC has been used for all mass spectrometry experiments as 
it is well suited to separating the peptides or proteins entering the mass 
spectrometer sufficiently to enable the maximum number of ions to be 
analysed.  Where possible separation of proteins on a denaturing 




A vital step in the development of mass spectrometry for proteomics was the 
development of ‘soft’ ionisation techniques.  Prior to the development of 
these techniques getting a sample into the gas phase and ionising it caused 
the fragmentation of large biomolecules beyond the ability of mass 
spectrometers to analyse.  The importance of viable ionisation strategies has 
been such that one half of the 2002 Nobel Prize in Chemistry was awarded to 
John Fenn [60] and Koichi Tanaka [61] for their work on electrospray 
ionisation (ESI) and matrix assisted laser desorption and ionisation (MALDI), 
respectively. 
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MALDI utilises a volatile matrix to lift peptides from a metallic surface upon 
excitation with laser light.  MALDI requires a simple mixture of proteins to 
work.  It can not be directly coupled to separation techniques and is difficult 
to automate so is labour intensive. 
 
Since the development of ESI [62] the technique has since gone on to become 
the most popular method of ionisation for mass spectrometry instruments 
with the possible exception of time-of-flight mass spectrometers which are 
frequently used with MALDI.  ESI is routinely used with ‘online’ separation 
techniques.  The eluate from the separation is pumped into an electrically 
charged glass needle.  At the tip the eluate is ejected as a charged droplet 
from which the solvent evaporates until the surface charge density is 
sufficient to desorb the solute ions [63].  The resulting ion is then taken in by 
the mass spectrometer for mass determination.   
 
1.3.3. Protein Identification 
Proteins are identified based on mass determination using mass 
spectrometry.  The mass analysers most frequently used in proteomics are 
time-of-flight (TOF), the closely related ion trap (IT) and quadrupole (Q), and 
fourier transform ion cyclotron resonance (FTICR). 
 
Protein identification follows two approaches; peptide mass fingerprinting 
and tandem MS.  In peptide mass fingerprinting the observed peptide 
masses are compared with peptide masses calculated using an in silico 
digestion approach from protein or gene sequences in a database.  The 
approach is limited in that relatively pure proteins or simple mixtures are 
required.  The separation techniques to achieve this are often extensive which 
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limits the throughput of such techniques.  Tandem MS combines the peptide 
mass data with the spectra generated by fragmenting the peptide ion in a 
collision cell.  In theory this approach can be used to completely sequence the 
peptide.  In practice analysis to this level is rarely used as it can be time-
consuming and identifications with a high degree of confidence can be 
achieved based on in silico analysis of sequence databases [57, 64].  During 
this thesis when tryptic peptides have been analysed it has been on a tandem 
mass spectrometer enabling the use of the more robust tandem mass 

























Figure 1.3  Schematic representation of a liquid chromatography tandem mass 
spectrometry instrument. 
The five principal components are; the liquid chromatography (LC) column, the 
electrospray ionisation source, the primary mass spectrometer, the collision cell and 
the secondary mass spectrometer.  Typically peptides are separated on the liquid 
chromatography column on the basis of hydrophobicity with more hydrophilic 
peptides eluting earlier.  The eluate from the LC column connects directly to the 
electrospray ionisation source.  The resulting stream of ions then enters the primary 
mass spectrometer which first surveys the m/z ratios of all the ions entering.  When 
an ion of interest has been identified it then switches mode to selectively allow that 
ion to pass through into the collision cell.  The ion then fragments and the resulting 
fragmentation ions enter the second mass spectrometer where their m/z ratios are 
measured.  The combination of the parent ion m/z ratio and the m/z ratios of the 
fragmentation products is highly specific and enables the peptide to be identified. 
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1.4. Quantitative Mass Spectrometry 
In addition to identifying proteins it would be advantageous to be able to 
also quantify them.  Techniques for the quantitation of single or small panels 
of proteins in a sample are well established and include approaches such as 
western blot and Enzyme-Linked Immunosorbent Assays (ELISA) utilising 
specific antibodies against the protein of interest.  In this thesis western 
blotting for specific proteins has been performed but there are limitations. 
Both ELISA and western blotting requires prior knowledge of the protein of 
interest and significant development time.  Mass spectrometry has long been 
used for the quantitation of small molecules and is now increasingly being 
used for the quantitation of large panels of proteins in biological samples.  To 
obtain robust quantitative data the peptide being quantified must be 
identified in all samples and must be unique for a particular protein.  The 
adoption of mass spectrometry in this context is hampered as in some ways it 
is ill suited to quantitation.  Although the spectra peak area corresponds to 
concentration the relationship is different for each compound or peptide. 
 
Due to differences in the physicochemical properties of peptides their 
detectability within the mass spectrometer varies.  For this reason it is 
difficult to compare two peptides or calculate their absolute concentration.  
Although absolute quantification would be advantageous, facilitating 
comparison between experimental data sets and laboratories, each peptide to 
be quantified must be synthesised so that it can be spiked into the sample at 
a known concentration.  This process is laborious and rarely done for 
discovery based studies [65].  Using computational techniques progress has 
been made [64, 66-68] with quantitation to the correct order of magnitude 
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now becoming viable [68].  A more common approach is to consider only 
relative quantification utilising stable isotopes, chemical tags and label-free 
approaches (Figure 1.4).  Despite significant differences in these approaches 
their performance is comparable.  In a comparison of DIGE, ICAT and 
iTRAQ by Wu et al each technique was found to have different limitations 
but differences in accuracy were marginal [69].  Analysis of a dataset using 
both SILAC and label-free methods showed SILAC to perform better for low 
abundance proteins with additional data processing required to achieve 
comparable performance [70].  This study used a spectral counting approach 
to label-free analysis which is known to lose linearity at low abundances.  A 
comparison of ICAT with label-free quantitation based on ion current area 
showed comparable performance between these techniques with spiked 
























Figure 1.4  Flowchart representing the main approaches used for quantitative 
mass spectrometry.   
Grey shapes represent pooled (black and white) samples.  The labelling and 
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1.4.1. Metabolic Labelling  
The earliest opportunity a tag or label can be incorporated is during 
synthesis.  To compare two samples a high percentage of a specific amino 
acid must include a heavy isotope in one of the samples and a light isotope in 
the other sample.  Achieving this discrepancy in cell culture is relatively 
straight forward and inexpensive as the volume and mass of the system is 
relatively low.  This technique is not generally thought to be suitable for 
larger intact organisms due to the prohibitive cost of the radioisotopes 
although variations to study tissues have been developed [72].  To reflect this 
limitation the technique is generally termed stable isotope labelling by amino 
acids in cell culture (SILAC) [73].  With different isotopes integrated into 
each sample they can be mixed and analysed on the mass spectrometer in the 
same run.  This avoids inter-run variation.  Due to the mass difference the 
peaks for the proteins in the two samples will be offset.  The area under each 
of the peaks can be calculated and compared giving the relative 
concentration of the parent protein in the two samples.  Although SILAC is 
not suitable for whole organism proteomics it is a good demonstration of the 
principals behind label based quantitative mass spectrometry.  As it is not 
possible to integrate labels into the proteome of a whole organism during 
formation alternative strategies have been developed to integrate them after 
collection. 
 
Of the techniques developed isotope-coded affinity tags (ICAT) and isobaric 
tag for relative and absolute quantitation (iTRAQ) have emerged as the most 
commonly used methods [74, 75].  Both these techniques involve additional 
experimental steps and potentially the inclusion of additional errors. 
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1.4.2. ICAT Labelling  
The ICAT reagent consists of three elements: a thiol specific reactive group 
which attaches the tag to each cysteine residue in proteins; a linker which 
contains 8 positions filled with either hydrogen, in the light form, or 
deuterium, in the heavy form; and finally a biotin group which is used to 
isolate the tagged peptides.  Two samples are labelled using different 
versions of the tag, mixed, digested with trypsin and then the labelled 
peptides isolated using the biotin group.  As not all peptides will contain a 
cysteine residue this isolation step will significantly reduce the complexity of 
the sample and enable a more complete analysis of those that remain.  The 
pooled samples are analysed on a mass spectrometer and the peptide peaks 
from each sample will be slightly offset due to the 8 Da difference in the mass 
of the tag [76].  
 
ICAT labelling occurs at the earliest point after collection which should 
minimise the effect of errors introduced during sample processing.  As the 
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1.4.3. iTRAQ  
The iTRAQ system utilises an amine specific reactive group to label all 
peptides in a sample.  Unlike ICAT where the intact protein is labelled, the 
iTRAQ labelling step occurs after protein digestion.  The amine reactivity 
and labelling post digestion should ensure that all peptides are labelled 
regardless of their composition.  As with ICAT quantitation, iTRAQ utilises 
stable isotopes but unlike ICAT the mass of the intact tag does not change 
(Figure 1.5).  This avoids issues with chromatographic separation.  This 
isobaric tag, in addition to the reactive group, contains two parts; a reporter 
group and a balance group.  Although the mass of each of these groups 
varies over the ranges 114.1-117.1 for the reporter and 28-31 for the balance 
group (there are four tags available with the classical iTRAQ system and now 
eight tags [77, 78] with a revised and expanded version rather than the two 
available with ICAT and most other labelling strategies) the overall mass of 
the two groups combined is kept constant using differential isotopic 
enrichment.  For example the 114.1 Da reporter group is exclusively attached 
to the 31 Da balance group and the 117.1 reporter group is attached to the 28 
Da balance group giving a consistent mass for the combined group of 145.1 
Da.  In the initial mass spectrum the peptides labelled with the four different 
tags all have the same m/z ratio and so appear as a single unresolved peak.  
Collision induced dissociation (CID) liberates the reporter group which, due 
to the difference in their masses resolve as discrete peaks enabling, by 
comparison of their intensities, the relative concentrations of their original 
peptides to be deduced.  The balance group is lost without charge and the 
fragments of the peptide originating from each sample are isobaric and so 
their ion signals are cumulative and reinforce the signal obtainable from any 
one sample analysed alone [79]. 











Figure 1.5  Schematic representation of the 4-plex version of isobaric tag for 
relative and absolute quantification (iTRAQ) quantitative mass spectrometry.   
Tryptic digests from four experimental conditions are labelled with isobaric tags.  
The mass of the reporter group in each tag varies but is compensated for by a 
change in the mass of a balance group so that the mass of the overall tag remains 
constant.  As the peptide passes through the first mass spectrometer the peptides 
appear identical.  Following fragmentation in the collision cell the reporter ions are 
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1.4.4. Label-free Quantitation 
Both ICAT and iTRAQ function because the spectral peak area of a species is 
proportional to the concentration of the measured species whether that 
species is a label or a peptide-label conjugate.  This relationship holds true 
for unlabelled peptides as well.  Thus, in theory at least, proteins can be 
quantified, relative to the same protein in other samples using mass 
spectrometry without labelling.  In the context of LC-MS/MS an ion 
chromatogram is extracted from the LC-MS/MS run and the peak area for a 
species integrated over the chromatographic timescale.  The area or intensity 
of the peak is then calculated and can be compared between runs.  The 
advantages include simplified sample preparation and the ability to compare 
an unlimited number of runs.  For comparison, ICAT is limited to directly 
comparing two samples [76] and iTRAQ to four [79] or eight [77, 78].  The 
disadvantage is that high reproducibility between runs is crucial.  This is not 
trivial with peptide elution times varying even between consecutive runs.  
Software has been developed to synchronize LC chromatograms between 
runs [80] but this is not an ideal solution and the possibility for errors 
remains and is less well understood than for labelling approaches such as 
ICAT and iTRAQ.   
 
With label-free quantitative LC-MS/MS it is important to balance the 
acquisition of survey spectra for quantitation and fragment spectra for 
identification.  LC supplies a near constant stream of new ions for analysis to 
the mass spectrometer.  For complex samples new ions may be supplied to 
the mass spectrometer faster than it can analyse them.  As a result some 
species will be skipped from the analysis.  The added time required to obtain 
detailed survey spectra in addition to the fragmentation spectra exacerbates 
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this problem.  This has led several groups to analyse each sample twice; once 
to obtain as many fragmentation spectra as possible for protein identification 
and a second time to obtain as many survey spectra as possible to ensure 
multiple samplings of the chromatographic peaks and accurate quantitation. 
 
1.4.5. Peptide Spiking  
So far the methods discussed have focused on relative quantitation between 
samples.  For the purposes of biomarker discovery relative quantitation 
between samples will likely be sufficient.  If absolute quantitation is required 
then the approach taken has been to synthesise peptides matching proteins 
of interest and spike them into samples.  As the concentration of these spiked 
peptides is known, comparison against them allows absolute quantitation.  
This approach means that you need to know in advance the proteins you 
want to quantify and requires significant preparation but remains the gold 
standard for absolute protein quantification.  This situation is similar to that 
for protein arrays and, as for protein arrays, peptide spiking is more suited to 
validation studies than discovery studies. 
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1.5. Biomarkers 
With the development of techniques for the large scale identification of 
proteins, interest has grown in studying tissues both directly and also 
indirectly via the body fluids.  Although much of the work within 
proteomics has focused on cataloguing what is present there has been 
growing interest in the use of proteomic techniques for biomarker discovery.  
The National Institutes of Health (NIH) [81] has defined a biomarker as, ‚A 
characteristic that is objectively measured and evaluated as an indicator of 
normal biological processes, pathogenic processes, or pharmacologic 
responses to a therapeutic intervention.‛  Within the context of proteomics 
the measured characteristic would be a protein.  The aim has, and continues 
to be, the identification of novel, hopefully superior, markers of disease 
enabling more timely and effective treatment.  Kidney and neurological 
disease are two areas where improved methods of detection and monitoring 
are particularly needed. 
 
1.5.1. Urine, biomarkers & AKI 
For many kidney diseases non-invasive diagnosis remains a significant 
challenge.  A biopsy is commonly required for an accurate diagnosis but this 
is an inherently invasive procedure.  The risk of an adverse event (such as 
haemorrhage) is increased by a variety of factors including obesity, severe 
hypertension and end stage renal disease (ESRD).  Although a biopsy is 
rarely indicated in ESRD [82, 83]  the need to control hypertension may delay 
biopsy.  Well characterised biomarkers detectable in the urine would provide 
safe, repeatable alternatives.   
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Acute kidney injury (AKI) is a serious medical condition which may occur 
following a variety of insults and is known to complicate treatment and have 
an adverse effect on mortality [84].  Around 19% of patients with moderate 
sepsis and 23% of patients with severe sepsis [85] will go on to develop AKI 
increasing mortality from 25-30% to 40-70% [86].  AKI is difficult to treat and 
early aggressive management is the principal approach taken.  As such, early 
diagnosis is important.  Although several potentially superior new 
biomarkers are undergoing late-stage clinical trials, currently AKI is 
diagnosed by observing increases in plasma creatinine and decreases in urine 
flow rates [84, 87].  Plasma creatinine is a function of creatinine generation, 
the volume of distribution and creatinine excretion.  Following a decrease in 
excretion it can be 48 hours before a change in plasma creatinine becomes 
apparent and 7 days before the extent of the change is known [84].  This 
assumes that the rate of production and volume remain constant which, 
particularly in conditions such as sepsis, will not necessarily be correct[88].  
Treatment and management of AKI will be most successful if started soon 
after injury.  Identifying novel biomarkers capable of identifying AKI before 
plasma creatinine changes has therefore been a priority. 
 
Several new proteins have been shown capable of detecting AKI before 
changes become apparent in plasma creatinine [89-92].  For example N-
acetyl-β-glucosaminidase (NAG), cystatin C, kidney injury molecule (KIM)-1, 
neutrophil gelatinase-associated lipocalin (NGAL) and IL-18 have each 
received considerable interest [89].  They have been found to increase as soon 
as 1 hour after injury [93] and up to 4 days before injury would be detected 
using serum creatinine [94].  NAG is a proximal tubule lysosomal enzyme.  It 
is elevated in the urine following tubular injury 12-96 hours prior to serum 
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creatinine although it can be elevated in some unrelated conditions [94].  
Cystatin C is a cysteine protease inhibitor which is produced by all nucleated 
cells and then filtered by the glomeruli before reabsorption by the tubule 
[89].  In this respect it is the novel biomarker most similar to serum 
creatinine.  In comparison to serum creatinine detection of AKI is possible 1-2 
days earlier with urinary cystatin C [95].  KIM 1 is a type I glycoprotein 
containing immunoglobulin-like and mucin domains.  KIM 1 mRNA levels 
increased more than any other gene in a rodent model of kidney injury [96].  
KIM 1 is expressed on the apical membrane ciliae of the proximal tubule 
where the ectodomain is shed into the lumen.  Urinary KIM 1 responds to 
injury more slowly than NGAL or IL-18 but is still elevated 12 hours after 
ischaemic insult [92].  NGAL was identified as one of several proteins 
increased more than 10-fold within hours of an ischaemic injury [93].  Via a 
siderophore NGAL binds iron ions and has been shown to be protective 
against ischaemic kidney injury [97].  Like NAG, it can be elevated in 
response to some conditions unrelated to AKI [89].  IL-18 is a pro-
inflammatory cytokine upregulated in the urine in response to ischaemia, 
inflammatory nephritis and nephrotoxicity.  An elevation in IL-18 can 
precede serum creatinine by 1-2 days [98].  Our understanding of AKI, 
although improved in recent years [99], is still far from complete and for this 
new generation of potential biomarkers there are still uncertainties.  
Additional study is required on these biomarkers and AKI in general to 
further improve diagnosis and treatment. 
 
The plasma [100], serum, ascites fluids [101, 102], amongst other biofluids 
together with tissue biopsies have all been investigated using proteomic 
techniques.  The urine has several advantages in certain situations [103].  The 
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collection of urine is non-invasive, straightforward and it is available in large 
volumes from almost all patients. Approximately 70% of the urinary 
proteome originates from the kidneys.  The remaining 30% being filtered 
from the circulation [104]. Therefore the urine is well-suited for the discovery 
studies designed to identify new biomarkers of kidney disease.  
 
Studying the urinary proteome also presents difficulties; the proteome varies 
diurnally within an individual, the protein concentration is relatively low 
and again may vary, and the urine contains a variety of interfering 
compounds including salts and organic compounds [104]. 
 
1.5.2. CSF and Neurological Disease 
Neurological diseases are a significant cause of morbidity and mortality.  In 
Europe, 23% of lost healthy years of life and 50% of years lived with 
disability are caused by neurological diseases [105].  The situation may 
worsen in the decades ahead because the incidence of Alzheimer’s disease, 
the commonest cause for dementia, is set to quadruple by 2050 [106].  
Diagnosis of neurological disease is often difficult, for example, despite 
intensive interest in biomarkers for Alzheimer’s disease over recent years we 
are still unable to monitor many aspects of disease progression [107].  In 
addition to ensuring that patients receive the correct care, reliable biomarkers 
able to track disease progression would significantly aid clinical trials for 
new therapies by providing surrogate endpoints. 
 
A biomarker present in the blood would be ideal due to the relative ease of 
collection but discovery is challenging.  The blood-brain barrier limits the 
flow of proteins from the central nervous system into the circulation.  
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Proteins which do reach the circulation must then be detected against the 
background of proteins released by other organs of the body and high 
abundant proteins such as albumin.  Given the difficulties with plasma 
proteomics and the high human and financial cost of neurological disease a 
growing number of publications have studied the proteome of the 
cerebrospinal fluid in search of biomarkers [108, 109].  Although potential 
candidates for a variety of diseases have been identified there remains a 
pressing need for further study. 
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1.6. Concluding Remarks 
 
We hypothesise that exosomes reflect the internal state of their cells of origin.  
We have explored this hypothesis via four distinct aims 
1. Development and validation of an exosome purification protocol in 
the urine. 
2. Investigate whether changes in exosomal protein faithfully reflect 
changes in the cell and whether the exosomes can transfer proteins 
between cells. 
3. Investigate whether exosomes are present in human CSF. 
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2.1. Biofluid preparation 
The protocol used for the collection and storage of a biofluid has an impact 
on the recovery of exosomes [110].  For the three fluids studied as part of this 
thesis the established protocols for exosome recovery from urine have been 
followed [110, 111]. Studies have demonstrated that protease inhibitors are 
not required for exosome isolation from human urine [112] and, as they may 
interfere with the proteomic analysis, they were omitted for these studies.  
For studies on tissue culture media and the CSF, where it is not yet clear 
whether protease inhibitors can be safely omitted, they have been used. 
 
The protease inhibitors used were leupeptin (Sigma, cat #L9783) and 
phenylmethylsulfonyl fluoride (PMSF; Sigma cat #P7626).  Leupeptin is a 
small peptide which binds to the active site of serine and cysteine proteases 
including plasmin, trypsin, papain and cathepsin B.  PMSF is a non-
competitive inhibitor which selectively forms a covalent bond with the active 
site serine in serine proteases.  It is highly effective but quickly degrades in 
aqueous solution.  For all samples sodium azide was added as a 
bacteriostatic agent.  By binding irreversibly to the heme cofactor of 




Urine was collected from healthy individuals, fellow students within the 
BHF/University Centre for Cardiovascular Science and from patients with 
sepsis.  Samples were obtained with informed consent and full ethical 
approval.  If not immediately processed the urine samples were stored at -
80°C.  When ready to be processed the urine samples were thawed with 
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vigorous vortexing when the sample was partially thawed and again when 
fully thawed [110].  After thawing the samples were kept on ice or stored at 4 
°C throughout processing.  Sodium azide (final concentration 3.34 mM) was 
added to samples once thawed as a preservative. 
 
2.1.2. CSF 
CSF was collected from patients undergoing thoraco-abdominal aortic 
aneurysm repair (with full ethical approval). This group was chosen as they 
have a CSF drain inserted peri-operatively as part of routine clinical 
management [113, 114].  Samples were aliquoted then stored at -80 °C until 
processing.  Samples were thawed with vigorous vortexing when the sample 
was partially frozen and again when fully thawed.  Protease inhibitors and 
preservative (final concentration: 3.34 mM sodium azide, 0.5 mM PMSF, 20 
µM Leupeptin) was added to the collected CSF.   
 
2.1.3. Media 
Cell culture media was collected and immediately frozen at -80 °C until 
processing.  Samples were thawed with vigorous vortexing when the sample 
was partially frozen and again when fully thawed.  Protease inhibitors and 
preservative (final concentration: 3.34 mM sodium azide, 0.5 mM PMSF, 20 
µM Leupeptin) was added to the collected media. 
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2.2. Exosome purification 
The biofluid samples were centrifuged at 15,000 x g for 10 minutes to pellet 
any shed cells, large membrane fragments and other debris.  The supernatant 
was then centrifuged at 200,000 x g for 60 minutes to pellet the low density 
membrane fraction.  The ultracentrifugation was performed using a Beckman 
Optima MAX-E ultracentrifuge and a MLA-80 rotor.  The k-factor for this 
rotor at 200,000 x g was 65.  The pellet was resuspended in phosphate 
buffered saline (PBS) (137 mM sodium chloride, 12mM sodium phosphate, 
2.7 mM potassium chloride; pH 7.4) and then centrifuged again at 200,000 x g 
for 60 minutes before resuspension again in PBS.  All centrifugations were 
performed at 4 °C.  The protein content of the low density membrane fraction 
was determined using the Bicinchoninic acid (BCA) protein assay kit (Pierce 
Cat # 23227) following the manufacturer’s instructions. 
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2.3. Protein Separation 
Electrophoresis separates compounds based on their ability to pass through a 
medium.  Denaturing polyacrylamide gel electrophoresis (PAGE) separates 
proteins based on their size.  The technique is used in conjunction with stains 
to visualise the molecular weight of the proteins present in a sample and as a 
preliminary step in western blots. 
 
2.3.1. Denaturing polyacrylamide gel electrophoresis (SDS-PAGE) 
Low density membrane samples were solubilised with 5x Laemmli sample 
buffer (0.5 M dithiothreitol (DTT), 10% sodium dodecyl sulphate (SDS), 14% 
sucrose, 0.01% bromophenol blue) and separated on a 1D SDS-PAGE gel.  
Pre-cast 12% gels from Bio-rad (cat # 1611102) and Thermo (cat # 25202) were 
used for the SDS-PAGE.  The buffer systems for these gels were different; the 
Bio-rad gels used a 2-Amino-2-hydroxymethyl-propane-1,3-diol (TRIS)-
Glycine system (25 mM TRIS, 192 mM Glycine, 0.1% SDS, pH 8.3), the 
Thermo gels used a TRIS - 2-[4-(2-hydroxyethyl)piperazin-1-
yl]ethanesulfonic acid (HEPES) system (Thermo 20X Tris-HEPES buffer, cat # 
28368).  The Bio-rad gels were run at 25 mA for 1 hour.  The Thermo gels 
were run at 100V for 45 minutes.  For both gel systems the Invitrogen 
SeeBlue Plus2 pre-stained standard (cat # LC5925) was used.   
 
During evaluation of the Agilent MARS column (see below), samples were 
separated using the Invitrogen NuPAGE Novex Bis-Tris 12% Mini Gel 
system (cat # NP0342BOX).  Samples were prepared following the 
manufacturer’s instructions with 4x lithium dodecyl sulphate (LDS) Sample 
Buffer (cat # NP0007) and 10x Sample Reducing Agent (cat # NP0004).  The 
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gels were run at 200V for 35 minutes using the 2-(N-
morpholino)ethanesulfonic acid (MES) buffer (cat # NP0002).  The Invitrogen 
SeeBlue pre-stained standard was used (cat # LC5625) with this gel system. 
 
2.3.2. Colloidal Coomassie Blue staining 
The molecular weight distribution of protein in a sample was assessed using 
a Coomassie stain [115].  The gel was fixed in a 7% glacial acetic acid, 40% 
methanol solution for 1 hour prior to the gel being stained using a Brilliant 
Blue G – colloidal concentrate (Sigma Aldrich, cat # B2025) stain following 
the manufacturer’s instructions.  The gel was briefly washed in a 25% 
methanol solution following which the gel was photographed.  Destaining 
was achieved with a 10% glacial acetic acid, 40% methanol solution. 
 
2.3.3. Coomassie blue staining 
During assessment of the Agilent MARS column the presence of protein in a 
sample was verified by running a small aliquot on a denaturing 
polyacrylamide gel and staining with a Coomassie based stain.  The gel was 
washed in deionised water three times for a total of 15 minutes and then 
GelCode Blue Safe Stain (Thermo Scientific, cat # 24594) added for 30-40 
minutes.  The gel was then destained in deionised water to visualise the 
protein.  All steps were performed on an orbital shaker. 
 
2.3.4. Methanol/Chloroform Protein Precipitation 
A methanol / chloroform protein precipitation was used when concentrated 
samples were required for electrophoresis.  To 1 part sample, 4 parts 
methanol was added and the sample vortexed until mixed. Then 1 part 
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chloroform was added, followed by vortexing, and then 3 parts distilled 
water and the sample again vortexed.  The sample was then centrifuged for 5 
minutes at 15000 x g.  Centrifugation separates the organic phase containing 
the chloroform from the aqueous phase.  The protein is concentrated at the 
liquid interface.  The aqueous top layer is discarded with care taken to avoid 
disturbing the interface and 4 parts methanol added to the organic phase and 
the protein at the interface.  The sample is then vortexed and centrifuged at 
15000 x g for 30 minutes.  The supernatant is then removed and the 
precipitate resuspended in fresh buffer.  All centrifugation steps are 
performed at 4 °C and the sample stored on ice. 
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2.4. Western blot 
Denaturing polyacrylamide gel electrophoresis was used to separate proteins 
based on molecular weight.  Following electrophoresis, the proteins were 
transferred to a PVDF membrane (Invitrogen cat# LC2002) using a 200 mA 
current for 1 hour.  The membrane was blocked with 5% fat-free milk in 
TBST (137 mM sodium chloride, 20 mM TRIS, 0.1% Tween 20; pH 7.5) and 
then probed with antibody to the protein of interest (Table 2.1).  The 
membrane was washed and then probed with an appropriate secondary 
antibody conjugated to horseradish peroxidase before visualisation using 
ECL western blotting analysis system (Amersham cat# RPN2109) and 
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2.4.1. Membrane Stripping 
Membrane stripping removes the antibodies used to detect a protein 
allowing the membrane to be probed with a different antibody.  This 
approach enables more information to be collected from a given amount of 
experimental sample. 
 
The PVDF membrane was washed 3 times in TBST for 2 minutes and then 
incubated in stripping buffer (0.1% SDS, 1% Tween-20, 0.2 M Glycine, pH 
2.2) for 10 minutes.  The buffer was then removed and replaced with fresh 
stripping buffer for a further 10 minutes after which it was again removed 
and replaced with TBST.  The membrane was washed 3 times with TBST for 
5 minutes.  To confirm that the attached antibodies had been successfully 
removed the membrane was treated with ECL reagent and then a 
photographic film was exposed to the membrane for 30 minutes.  On 
developing, the film should be clear.  The membrane was washed a further 3 
times with TBST before being reprobed. 
 
2.4.2. Ponceau S Staining 
Ponceau S staining was used to visualise the proteins adhering to the PVDF 
membranes following transfer.  The membrane was washed 3 times in 
distilled water for 5 minutes and then stained with Ponceau S solution (Fluka 
cat # 81462) for 5 minutes.  The membrane was then washed again 3 times in 
distilled water for 5 minutes to remove background staining.  The membrane 
was photographed and then washed with distilled water before destaining 
using 0.1 N NaOH for 30 seconds.  The membrane was then washed with 
distilled water 3 times for 2 minutes and then with TBST 3 times for 2 
minutes. 
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2.5. Isopycnic Centrifugation 
Exosomes have been shown from previous reports to have a characteristic 
density of 1.10 – 1.15 g.cm-3 [23, 40].  Using isopycnic centrifugation it is 
possible to separate particles based on their density.  A variety of solutes can 
be used to establish a density gradient through which a particle will migrate 
until the density of the surrounding solution matches its own density.  Once 
equilibrium has been reached centrifugation can stop and fractions collected 
of known density.  Sucrose has widely been used as the solute of choice for 
density gradients for the isolation of exosomes.  Changing the solute can 
subtly alter the density to which a particle localises and so sucrose was used 
to allow consistency with prior studies. 
 
The resuspended low density membrane fraction was diluted into the top 
fraction of a step gradient comprising layers of 2, 1.3, 1.16, 0.8, 0.5 and 0.25 M 
sucrose in a Beckman ultraClear tube (cat # 347356).  The gradients were 
centrifuged for 2.5 hours at 200,000 x g in a Beckman TLS-55 rotor.  Six 
fractions were collected from the gradient and stored for density 
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2.6. Visualisation of Exosomes 
Exosomes have a diameter of 20 – 100 nm and a distinctive shape [10, 40, 
116].  Visualising structure at this scale is not possible with standard light 
microscopy due to diffraction limits using wavelengths visible to the human 
eye.  Electron microscopy, due to the shorter wavelength of the electrons, can 
visualise structures at this scale.  The protocol followed is based on several 
previously published [10, 116] with variations made to better match the 
equipment available. 
 
2.6.1. Transmission Electron Microscopy (TEM) 
Following isolation of the exosomes using ultracentrifugation the 
resuspended sample was mixed 1:1 with 4% paraformaldehyde.  A drop of 
this solution was placed on a Petri dish and then a formvar coated 200 mesh 
gold grid (Taab cat# F218/G025) floated on top for 20 minutes.  All 
subsequent steps are performed in the same way.  The grid was moved to 
PBS for a two 5 minute washes. Then the exosomes were re-fixed on the grid 
using a 1% glutaraldehyde solution.  The grid was again washed twice in 
distilled water for 5 minutes.  Finally the grid was transferred to a drop of 
0.5% uranyl acetate / 2% 25 centipoise methyl cellulose (Sigma Aldrich cat 
#M6385).  Following staining for 5 minutes excess fluid was removed, the 
grid allowed to air dry and then examined on a Phillips CM120 BioTwin 
transmission electron microscope. 
 
2.6.2. Immuno-TEM 
The low density membrane fraction was mixed 1:1 with 4% 
paraformaldehyde.  A drop of this solution was placed on a Petri dish and 
  49 
then a formvar coated 200 mesh gold grid (Taab cat# F218/G025) floated on 
top for 20 minutes.  All subsequent steps were performed in the same way 
with washing between each step.  The grid was blocked for 5 minutes with 
0.05 M Glycine / PBS then 1% BSA / PBS, then transferred to a 1:200 dilution 
of the antibody of interest or appropriate isotype control in 0.02% Triton X-
100 PBS for 45 minutes at room temperature. Then the grid was incubated 
with a 1:40 dilution of a 10 nm gold conjugated anti-mouse IgG antibody for 
60 minutes at room temperature. Finally the grid was incubated with 1% 
glutaraldehyde for 5 minutes,  then contrasted and embedded with 0.5% 
uranyl acetate / 2% methyl cellulose.  Excess fluid was removed, the grid 
allowed to air dry and then examined on a Phillips CM120 BioTwin 
transmission electron microscope. 
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2.7. Protein digestion using trypsin 
Tandem mass spectrometric analysis of tryptic digests provides more robust 
identification of proteins than mass spectrometric analysis of intact proteins.  
Protein digestion with trypsin can be performed in a number of ways with 
the optimal approach dependent on the experimental design and the sample 
being studied. 
 
2.7.1. In-gel tryptic digestion 
The SDS-PAGE gel was sliced into ten sections and then each slice was cut 
down to gel cubes approximately 1mm in size.  These gel pieces were then 
washed in distilled water for 15 minutes. The distilled water was removed 
and 50% acetonitrile added for a further 15 minutes.  This was then removed 
and replaced with fresh 50% acetonitrile. The solution was then replaced 
with 100 mM ammonium bicarbonate for 5 minutes. Then an equal volume 
of acetonitrile was added for a 15 minute incubation.  The solution was then 
removed and the gel pieces dried in a speed vacuum at 60 °C for 45 minutes. 
 
The cysteine residues in the proteins were then reduced and alkylated.  A 10 
mM DTT / 100 mM ammonium bicarbonate solution was added to the gel 
pieces and they were then incubated at 56 °C for 45 minutes without 
agitation.  The samples were allowed to cool and then an equal volume of 55 
mM iodoacetamide / 100 mM ammonium bicarbonate was added and the gel 
pieces incubated in the dark for 30 minutes.  The solution was removed and 
replaced with 100 mM ammonium bicarbonate.  Following incubation for 5 
minutes, an equal volume of acetonitrile was added and incubation 
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continued for 15 minutes.  The solution was removed and the gel pieces 
dried in a speed vacuum. 
 
The proteins were then digested by adding a sufficient volume of 0.1 µg/µl 
sequencing grade modified trypsin (Promega cat #V5111) to re-hydrate the 
gel pieces.  The gel pieces were incubated on ice for 45 minutes after which 
any excess solution was removed and sufficient buffer solution added to 
cover the gel pieces which were then incubated at 37 °C overnight without 
agitation.  The following morning the solution was removed and stored on 
ice.  Ammonium bicarbonate (25 mM) was then added to the gel pieces and 
incubated for 15 minutes.  An equal volume of acetonitrile was then added 
and again incubated for 15 minutes.  This solution was then removed and 
pooled with the overnight supernatant.  Formic acid (5%) was then added to 
the gel pieces and incubated for 15 minutes before an equal volume of 
acetonitrile was added and again incubated for 15 minutes.  The solution was 
removed and pooled with the previous supernatant and the gel pieces 
incubated with 5% formic acid and then acetonitrile as before.  The solution 
was again removed and pooled with the previous supernatants and then 10 
mM DTT was added to give a final concentration of 1 mM DTT.  The 
supernatant was then completely dried in a speed vacuum at 60 °C and the 
residue stored at -80 °C until processing on the mass spectrometer. 
 
2.7.2. In-solution digestion 
Following purification using methanol / chloroform precipitation the 
proteins were resuspended in 50 mM ammonium bicarbonate solution to a 
concentration of 12 pmol/µl calculated on the assumption that the mean 
molecular weight of a protein is 50 kDa.  The proteins were then reduced by 
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incubation at 50 °C for 15 minutes with a 50 fold molar excess of DTT.  To 
prevent the disulphide bonds reforming the cysteine and methionine 
residues were capped with alkyl groups to form stable derivatives by 
incubation at room temperature with a 2 fold molar excess of iodoacetamide 
to DTT.  Sequencing grade modified trypsin (Promega cat # V5111) was 
reconstituted in the supplied resuspension buffer and then added to the 
protein sample to a ratio of 1 part protease to 50 parts protein by weight.  The 
samples were then incubated at 37 °C overnight.  The enzymatic reaction was 
stopped by the addition of trifluoroacetic acid to a final concentration of 10%. 
 
 
2.7.3. On-filter digestion 
Sample was loaded on the molecular filter which was centrifuged at 12000 x 
g for 45 minutes, the molecular filter tube was refilled with 100 mM 
ammonium bicarbonate and the filter again centrifuged for 45 minutes.  DTT 
was then added to the tube at a 50 fold molar excess to the estimated protein 
present and the tube incubated at 50 °C for 15 minutes.  Iodoacetamide was 
then added at a 2 fold molar excess to the DTT and the tube kept in the dark 
for 15 minutes at room temperature.  Sequencing grade modified trypsin 
(Promega cat #V5111) was then added at 20 fold less than the estimated 
protein present.  The tube was incubated overnight at 37 °C and then 
centrifuged at 12000 x g for 45 minutes with the eluate collected. Ammonium 
bicarbonate (50 µl 100 mM) was added to the filter which was again 
centrifuged and the eluate collected.  Finally 50 µl of 10% acetonitrile was 
added and the filter again centrifuged with the eluate collected.  The 
collected eluates were pooled and trifluoroacetic acid was added to a final 
concentration of 10%. 
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2.7.4. Quantitative MS on spiked samples 
Label-free quantitative mass spectrometry was performed on samples spiked 
with peptides following digestion and spiked with proteins prior to 
digestion in two separate experiments.  For the first experiment a sample of 
purified urinary exosomes was run briefly on a SDS-PAGE gel and the 
proteins digested and extracted following the in-gel digestion protocol.  The 
resulting peptides were then split into two aliquots.  Each aliquot was spiked 
with 5 peptides to represent 1% and 4% of total protein by mass.  These 
peptides, all obtained from Sigma-Aldrich, were Angiotensin II acetate (Cat# 
A9525), Osteocalcin fragment 7-19 (Cat# O3632),  Gly-Glu-Gln-Arg-Lys-Asp-
Val-Tyr-Val-Gln (Cat# G3774), Chromostatin-20 (Cat# C1680) and 
Chromogranin A (Cat# C6446).   These peptides were chosen because they 
had been used in a previous peptide spiking study [117].  The two aliquots 
were then analysed using LC-MS/MS.  The peaks corresponding to the 
spiked peptides were then located in the spectra using the DataAnalysis 
software and the area of the peaks compared between the samples.   
 
For the second experiment a sample of urinary exosomes was split into two 
aliquots and then spiked with the SDS-PAGE low range molecular weight 
standard (Bio-Rad cat# 161-0304) containing six proteins (phosphorylase b, 
bovine serum albumin, ovalbumin, carbonic anhydrase, trypsin inhibitor and 
lysozyme) to represent 1% and 4% of total protein by mass.  Each aliquot was 
then briefly run on an SDS-PAGE gel before the proteins were digested with 
trypsin and extracted from the gel following the in-gel digestion protocol.  
The two aliquots of extracted peptides were then analysed by LC-MS/MS.  
The peptides derived from the spiked proteins were identified by querying 
the MASCOT software.  The peak area for each of the identified peptides was 
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measured using the DataAnalysis software and then compared between the 
two aliquots. 
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2.8. Immunoglobulin depletion 
2.8.1. Immunoglobulin depletion using Protein G 
The purified exosomes were mixed with 1.25 mg Protein G immobilized on 
cross-linked 4% agarose  beads (Fluka cat #83219) and incubated at room 
temperature for 10 minutes.  The agarose beads were pelleted by 
centrifugation at 2000 x g for 5 minutes and the supernatant collected.  The 
beads were then washed with PBS solution, centrifuged again and the 
supernatants pooled. 
 
2.8.2. Immunoglobulin depletion using Agilent Multiple Affinity 
Removal System (MARS) column 
The proteins in the purified exosomes were extracted using a 
methanol/chloroform precipitation and then resuspended in an 8M urea 
solution which was immediately diluted to 4M.  The Agilent MARS column 
is sensitive to organic solvents and a urea solution is used to elute bound 
proteins from the column.  For the column to function correctly it is therefore 
necessary to replace the buffer.  This was achieved by dilution into the 
sample buffer for the MARS column and subsequently concentrating the 
sample on a Microcon Ultracel YM-3 molecular filter (Millipore cat #42403).  
The filter loaded with the sample was centrifuged at 12000 x g for 45 minutes, 
the sample again diluted with sample buffer and the filter centrifuged again.  
In total this process of dilution and centrifugation was repeated three times.  
The sample was then run on the MARS column following the manufacturer’s 
instructions and the low abundance and high abundance protein fractions 
collected.  The collected volume was approximately 400 µl for the low 
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abundance proteins and 1.5 ml for the high abundance proteins.  These 
samples were then concentrated on molecular filters prior to analysis. 
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2.9. Mass Spectrometry 
Two different types of mass spectrometers were used based on the type of 
sample being analysed. 
 
2.9.1. GeLC-MS/MS 
An aliquot of resuspended exosomes were run on a Bio-Rad SDS-PAGE gel 
to fractionate the proteome.  The gel was then stained with colloidal 
coomassie blue stain (Sigma-Aldrich Cat# B2025-IEA) to visualise the 
proteins and the protocol for in-gel tryptic digestion followed.  The 
resuspended tryptic peptides were then separated on a Dionex UltiMate 3000 
series HPLC instrument with a Dionex Pepmap100 75 µm by 15 cm column 
with a 300 µm by 5 mm trap column maintained at a constant temperature of 
40 °C.  The loaded peptides were eluted from the column by an acetonitrile 
solution which increased in concentration from 5% to 72% over 35 minutes.  




In addition to GeLC-MS/MS the proteome of the CSF derived exosomes was 
also investigated using LC-MS/MS.  This was done in preparation for a 
quantitative analysis for which separation on a gel can negatively impact 
reproducibility.  The proteins present in the CSF exosomes were separated 
from the lipid components using a methanol / chloroform precipitation.  A 
SDS-PAGE gel was then run on a small aliquot to verify the presence of 
protein and then an in-solution digest was used to generate tryptic peptides.  
The resuspended tryptic peptides were separated on a Dionex UltiMate 3000 
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series HPLC instrument with a Dionex Pepmap100 75 µm by 15 cm column 
with a 300 µm by 5 mm trap column maintained at a constant temperature of 
40 °C.  The loaded peptides were eluted from the column by an acetonitrile 
solution which increased in concentration from 5% to 72% over 35 minutes.  




2.9.3. LC-FTICR whole protein MS 
Following resuspension of the methanol / chloroform precipitation pellet, the 
proteins were separated on a Dionex UltiMate 3000 series HPLC instrument.  
The eluate was connected to the ESI source on a Bruker Daltonics 12T SolariX 
Fourier Transform Ion Cyclotron Resonance Mass Spectrometer (FT-ICR MS) 
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2.10. Cell culture 
To study exosome release and also assess the biological role of exosomes an 
in vitro cell model has been used.  Murine cortical collecting duct (mCCD) 
cells [118] were used as a model kidney cell line. 
 
2.10.1. Media 
The mCCD cells were cultured in Dulbecco’s Modified Eagles Media 
(DMEM) / F12 Media 1:1 (Gibco cat #31331) supplemented with 10 ml foetal 
calf serum (Invitrogen cat #10270-106), 5 ml Insulin Transferrin Selenium 
(ITS) solution (Gibco cat #41400-045), 5 ml Penicillin Streptomycin 
(Invitrogen cat #15140-122), 50 µl 500 nM Dexamethasone (Sigma Aldrich cat 
#D2915), 500 µl 1 µM T3 (Sigma Aldrich cat #T6397) and 500 µl 10 µg/ml EGF 
(Sigma Aldrich cat #E4127). 
 
2.10.2. Cell passaging 
The mCCD cells were grown to near confluency in tissue culture treated 
flasks prior to passaging.  Cells were passaged by removing the media and 
twice incubating the cells with DPBS supplemented with 1 mM 
Ethylenediaminetetraacetic acid (EDTA) for 10 minutes.  This solution was 
then replaced with 1ml of trypsin EDTA solution (Lonza cat #BE17-161E) for 
each 25 cm2 of flask surface and the cells incubated at 37 °C for 
approximately 10 minutes or until the majority of the cells had detached 
from the flask surface.  The resuspended cells were then diluted with a 6 fold 
excess of fresh media and then one quarter of the resuspended cells seeded 
onto fresh flasks. 
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2.10.3. Exosome depleted media 
Purification of exosomes from the tissue culture conditioned media assumes 
that the exosomes present are released by the cells.  Serum is a rich source of 
exosomes and other small lipid membrane bound vesicles which unless 
removed will interfere with the detection of exosome release from the cells.  
Unfortunately without foetal calf serum supplemented into the tissue culture 
media cell viability is compromised.  Exosome depleted foetal calf serum was 
made by diluting the foetal calf serum with media to a concentration of 20% 
which reduced the viscosity of the solution facilitating the pelleting of the 
exosomes under centrifugation.  The 20% foetal calf serum solution was 
centrifuged overnight at 200,000 x g.  The supernatant was removed and 
transferred to fresh tubes before being centrifuged for a further hour at 
200,000 x g.  The supernatant was again removed and after being filtered 
through a 0.22 µm cellulose acetate filter could be used in tissue culture 
without interfering with the detection of exosomes released from the cells. 
 
2.10.4. AnnexinV/PI apoptosis/necrosis determination 
The Annexin-V-FLUOS staining kit (Roche, cat # 11 858 777 001) was used for 
quantification of apoptosis and necrosis.  Firstly the cells were released from 
the flask surface by treatment with trypsin.  Following the protocol for 
passaging, the cells were incubated twice with PBS supplemented with 1 mM 
EDTA at room temperature for 10 minutes.  This was then replaced with 
trypsin solution and incubated at 37 °C.  Once the cells had detached from 
the flask surface a 6 fold excess of media to trypsin was added to neutralise 
the trypsin and the cells pelleted at 500 g for 3 minutes.  The cells were 
resuspended in PBS and then centrifuged again before resuspension in the 
incubation buffer supplied with the kit.  The resuspended cells were then 
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split into two tubes.  One tube was supplemented with the incubation buffer 
only and the second tube supplemented with incubation buffer plus 
Annexin-V-Fluorescein each to a final volume of 0.5 ml.  After incubation at 
room temperature for 10 minutes each sample was analysed on a BD 
Biosciences FACS Calibur.  Propidium iodide was then added to the 
Annexin-V-Fluorescein labelled sample and analysed immediately on the 
FACS Calibur.  The Fluorescein response was measured on the FL1 channel 
and the propidium iodide response was measured on the FL3 channel. 
 
2.10.5. Stimulation with ionomycin/vasopressin/cisplatin 
Flasks of confluent cells were washed in foetal calf serum free media and 
then media containing exosome depleted foetal calf serum added.  
Ionomycin (Sigma Arich cat #I0634), desmopressin (dDAVP; Sigma Aldrich, 
cat #V1005), and cisplatin (Calbiochem, cat #232120) were diluted in serum 
free media and then added to the flasks at the necessary concentration.  The 
mCCD cells were stimulated with ionomycin for 2 hours and cisplatin for 48 
hours after which the media, and for the cisplatin treatment the cells, were 
collected.  Stimulation with desmopressin lasted 96 hours.  The media was 
collected at 48 hours and then replaced.  Both the cells and the media were 
collected at 96 hours.  For each stimulation collection of the cells was 
achieved by scraping them into ice cold RIPA solution (50 mM TRIS, 150 mM 
NaCl, 2 mM EDTA, 1% Triton X-100, 0.1% SDS; pH 7.4) after first washing 
the cells in DPBS.  The cell suspension was then centrifuged for 5 minutes at 
15,000 x g and the supernatant stored at -80 °C prior to analysis. 
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2.10.6. Effect of added exosomes 
Cells were grown to confluency in two T150 flasks and then stimulated with 
3.16 ng/ml dDAVP or left unstimulated for 96 hours.  The media was 
changed at 48 hours.  The media was collected at 96 hours and the exosomes 
purified.  The protein concentration in the purified exosome samples was 
measured using the BCA assay.  The mCCD cells were passaged and then 
grown to confluency in a 12-well plate.  The purified exosomes were added 
to a well at a concentration of 50 µg/ml.  Stimulation with 3.16ng/ml dDAVP 
was used as a control.  After incubation for 48 hours the cells were washed 
with DPBS and then scraped into ice cold RIPA solution.  The cell suspension 
was then centrifuged for 5 minutes at 15,000 x g and the supernatant stored 
at -80 °C prior to analysis. 
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2.11. Data Analysis 
Data generated by FACS was analysed using the BD Biosciences CellQuest 
software package.  The intensity of bands on western blots was measured 
using the BioRad Quantity One v4.5.0 software package.  The DataAnalysis 
v1.3 software package from Bruker Daltonics was used for the analysis of the 
mass spectrometry data in chapter 3.  Version 1.4 was used in chapters 5 and 
6.  The Progenesis LC-MS v2.6 software package from Non-linear Dynamics 
was used for the quantitative mass spectrometry in chapter 6 following pre-
processing using the DataAnalysis software.  The MASCOT server from 
Matrix Science [119] was used to identify proteins from the MS/MS data.  
Information on the identified proteins was gathered using the Harvester 
website [120] which includes the Online Mendelian Inheritance in Man 
(OMIM) website [121].  The Exocarta website was used to find previous 
instances of a protein being detected in exosomes [122].  Data analysis was 
performed in the python language with the Scipy [123] and Matplotlib [124] 
packages used for general statistical analysis and data visualisation 
respectively.  Experimental measurements were summarised with mean and 
SEM.  Statistical significance was accepted at p<0.05. 
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3.1. Introduction 
Urine is enriched for organ-specific proteins originating from the kidney and 
urinary tract [125] and is the logical biofluid to study to identify kidney 
disease biomarkers [103].  There are significant challenges to overcome if a 
study is to be successful. The urinary proteome is more dilute than the 
plasma (although this is somewhat mitigated by the ease of collecting urine 
in comparatively large volumes), analysis is often complicated by interfering 
compounds such as salts and, although less complex than the plasma 
proteome, it is still sufficiently complex to present a challenge [126].  The 
soluble urinary proteome includes proteins filtered from the plasma and 
proteins released directly by the kidneys [104].  Exosomes should be enriched 
for proteins released by the kidneys and present a partial solution to the 
complexity and large dynamic range of the urinary proteome [127]. 
 
Several groups have previously reported the presence of exosomes in urine 
[10, 40]. The first objective of this chapter was to establish a protocol for the 
purification of exosomes from human urine and confirm their presence using 
established criteria [1]. 
 
The second objective was to explore the proteome of the urinary exosomes 
using mass spectrometry and so expand the list of currently identified 
exosomal proteins. 
 
The third objective was to investigate whether the exosomal proteome 
changes with disease.  The usefulness of the exosomes as a source of 
biomarkers is dependent on the exosomal proteome changing in response to 
disease state. 
  66 
 
The fourth objective was to investigate the ability of label-free quantitative 
mass spectrometry to accurately quantify changes in protein concentrations 
between samples.  Label-free quantitative mass spectrometry has potential 
advantages over other methods of proteome-wide quantitation but is a 
relatively new technique and validation of the approach is needed before 
committing to a large scale study which depends on the technique. 
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3.2. Methods 
This study was performed with local ethical approval (MREC number: 
06/MRE00/67) and informed consent was obtained from all participants or 
their next of kin. Healthy, male volunteers (aged 27±3.27) were recruited 
from the Queen’s Medical Research Institute, University of Edinburgh.  
Subjects with sepsis (Table 3.1) were recruited from the Intensive Therapy 
Unit, Edinburgh Royal Infirmary. Urine was collected in the morning using 
sterile 50 ml centrifuge tubes.  The method used for the purification of 
exosomes is described in Chapter 2.1.1.  Briefly, urine was centrifuged at 
15,000 x g to pellet any cell debris and then the supernatant was centrifuged 
at 200,000 x g to pellet the exosomes.  The presence of exosomes was verified 
using SDS-PAGE (Chapter 2.3.1.), western blot (Chapter 2.4.), isopycnic 
centrifugation (Chapter 2.5.) and transmission electron microscopy (Chapter 
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Sepsis 1 Sepsis 2 Sepsis 
and AKI 1 
Sepsis 
and AKI 2 
Sepsis 
and AKI 3 
Sex F F F M M 
Age 25 40 22 70 61 
Temperature 
(°C) 




87 85 70 95 70 
Heart rate 
(BPM) 
115 90 130 105 120 
Respiratory 
rate (min-1) 
33 28 >20 35 26 
pO2  (kPa) 9.7 13.16 15.51 12.65 12.42 
pCO2  (kPa) 7.99 6.15 6.35 3.12 4.43 
H+ (nM) 58.7 37.5 48 23.5 38.1 












59 84 355 258 237 
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Sepsis 1 Sepsis 2 Sepsis 
and AKI 1 
Sepsis 
and AKI 2 
Sepsis 




18 3 10 11 39 
Haemoglobin 
(g/L) 
97 69 63 68 84 
WCC 
(x109/L) 
35.4 11.2 28 15.7 12.3 
Platelets 
(x109/L) 
38 389 441 633 232 
Urine output 
in 24 hrs 
(mL) 
1130 2256 1500 3855 3252 
Table 3.1 Demographic and physiological information on the five patients 
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The proteome of the urinary exosomes was investigated using GeLC-MS/MS 
as described in Chapter 2.9.1. To reduce the complexity of the sample 
entering the mass spectrometer GeLC-MS/MS separates the proteome based 
on the size of the intact proteins using SDS-PAGE.  In-gel tryptic digestion is 
performed on gel slices and the extracted peptides are then separated based 
on their hydrophobicity using HPLC prior to tandem mass spectrometry.  
The resulting data was analysed on the Bruker DataAnalysis software 
package.  The MASCOT server version 2.2 from Matrix Science [128] was 
used to identify proteins from the MS/MS data.  Mascot searches were 
performed on the NCBI (NCBI_Fi 20080229) database (6251073 sequences) 
restricted to Homo sapiens (199930 sequences) with the following parameters: 
a specified trypsin cleavage with a maximum of 1 possible missed cleavages, 
precursor and fragment ion tolerances of ±1.2 Da and ±0.6 Da respectively, 
fixed modification caused by carbamidomethylation on cysteines and 
variable modification by oxidation on methionine.  Individual ion spectra 
were accepted at scores equivalent to p < 0.05. 
 
Label-free quantitative mass spectrometry was performed on samples spiked 
with peptides following digestion and spiked with proteins prior to 
digestion.  The complete protocol for each experiment is documented in 
chapter 2.7.4.  Briefly, for the first experiment two aliquots of purified 
urinary exosomes digested with trypsin were spiked with 5 peptides to 
represent 1% and 4% of total protein by mass.  The two aliquots were then 
analysed by LC-MS/MS.  The peaks corresponding to the spiked peptides 
were then located in the spectra and the area of the peaks compared between 
the samples.   
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For the second experiment two aliquots of urinary exosomes were spiked 
with six proteins to represent 1% and 4% of total protein by mass.  GeLC-
MS/MS was performed on each aliquot.  The peptides derived from the 
spiked proteins were identified by querying the MASCOT software.  The 
peak area for each of the identified peptides was measured and then 
compared between the two aliquots. 
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3.3. Results 
3.3.1. Exosome detection in human urine 
To investigate whether exosomes were being purified from the urine in the 
ultracentrifuge pellet the components of the supernatant and pellet were 
separated by SDS-PAGE and probed for three markers of exosomes.  TSG101 
is a component of the ESCRT-I complex which is involved in the formation of 
the intralumenal vesicles which are eventually released as exosomes [1].  
Flotillin 1 is thought to be present at the site of exosome formation and 
incorporated in their proteome [1].  CD24 is a GPI-linked mucin-like 
adhesion molecule demonstrated to be a marker of urinary exosomes [40].  
TSG101, flotillin 1 and CD24 are all present in the ultracentrifuge pellet but 


























Figure 3.1  Western blot for exosomal markers. 
In human urine the exosomal markers A) TSG101, B) CD24 and C) flotillin 1 
are enriched in the ultracentrifuge pellet compared with the supernatant.  
Each panel is representative of three separate experiments.  
 
 







Figure 3.2  Western blot on isopycnic centrifugation fractions. 
In human urine, the exosomal markers flotillin 1, TSG101 and CD24 localise 
to a density of 1.12-1.16 g.cm-3 on a sucrose density gradient following 
isopycnic centrifugation.  This distribution was consistent across five 
biological replicates with the exosomal markers within the range 1.10-1.17  
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The components of the ultracentrifuge pellet were separated by isopycnic 
centrifugation on a density gradient to investigate whether the markers are 
present at the characteristic exosomal density of 1.10-1.15 g.cm-3  [116].  From 
the density gradient six fractions were collected with the exosomal markers 
localised in fractions 3 and 4 (Figure 3.2).  This corresponded to a density of 
1.12-1.16 g.cm-3. 
 
As a final step in verifying that exosomes are present in the ultracentrifuge 
pellet they were directly visualised by transmission electron microscopy.  
Several structures of the characteristic size of 20-100 nm and cup-shaped 























Figure 3.3  Transmission electron micrograph of embedded and negatively 
stained human urinary exosomes.   
Exosomes have previously been described as 20-100 nm in diameter and cup-
shaped in appearance.  Several structures of the characteristic size and 
appearance of exosomes are highlighted by arrows. 
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3.3.2. Analysis of the urinary exosomal proteome 
With the presence of exosomes established their proteome was investigated 
by GeLC-MS/MS. The urinary exosomes of a healthy volunteer were 
analysed.  The gel was sliced into 10 sections during GeLC-MS/MS.  The 
slices were not equally spaced through the gel.  Instead slice boundaries were 
chosen to limit the presence of the high abundance proteins to the smallest 
sections of gel possible (Figure 3.4).  Using this technique 76 proteins were 
identified (Table 3.2 and Appendix 1).  Further information on these 
identified proteins was collected from the harvester website [120].  42% of the 
identified proteins were cytoplasmic in origin, 30% were either integral or 
linked to the plasma membrane, 15% were from other sections of the cell and 
13% were extracellular in origin (Figure 3.5).  A small number of the 
identified proteins have previously been shown to be specific to various 
sections of the kidneys (Figure 3.6).  The identified proteins were queried in 
the Online Mendelian Inheritance in Man (OMIM) database [121] which 
revealed that 9 of the identified proteins were linked to renal disease and a 

















Figure 3.4  A human urinary exosomal protein sample run on a 1D SDS-
PAGE gel and stained with colloidal brilliant blue.   
Urinary exosomes from one individual were used.  The gel was sliced into 10 
sections, shown along the left edge.  The proteins in each section were then 
digested with trypsin and the peptides identified using mass spectrometry.  
The number of proteins identified in each section is shown along the left 
edge of the gel.  The markers present in the ladder are labelled on the right. 
 
































3 266 [10, 129-131] 
Alix 2OEX_A 2 73 [130, 132-134] 
Annexin A11  NP_001148 3 73 [10, 130-132] 
Annexin A2 isoform 2  NP_004030 2 59 [132] 
Annexin A4 AAC41689 2 46 [10, 130-132, 134] 
RAB10, member RAS oncogene family NP_057885 3 45 [10, 130-132] 












3 266   
Polyubiquitin  BAA23486 2 266   
Lactate dehydrogenase B  NP_002291 4 157 [10, 130-133, 135] 
Olfactomedin 4 AAH47740 3 153 [10, 131, 134] 
Glyceraldehyde-3-phosphate dehydrogenase  CAA25833 3 147 [131] 
FBP aldolase I a BAF83484 3 137 [10, 131, 132, 134-
136] 
S100 calcium-binding protein A9  NP_002956 2 131 [131, 134] 
BROX NP_653296 3 116 [10, 130-132, 134] 
Carbonic anhydrase II  NP_000058 1 93 [10, 131] 
Tyrosine 3/tryptophan 5 -monooxygenase 
activation protein, epsilon polypeptide  
NP_006752 1 93 [10, 130-134] 
Protein expressed in prostate, ovary, testis, 
and placenta 2  
NP_001077007 3 93 [132] 
2-phosphopyruvate-hydratase alpha-enolase; CAA59331 2 89   
   
carbonate dehydratase  
Enolase 3 CAA34513 2 79 [10, 130] 
Lactate dehydrogenase A BAC85389 2 76 [10, 29, 130-132] 
Calbindin D28K  AAB19408 1 76 [10, 131] 
Peptidylprolyl isomerase A (cyclophilin A) NP_066953 2 74 [10, 129-132, 134, 
135] 
c-myc binding protein  EAX07292 2 64   
G protein beta subunit AAA35922 2 60   
S100 calcium binding protein A8 CAA68390 2 59 [131, 134] 
Alpha globin  CAA23749 1 55   
Phosphoglycerate kinase 2 CAA28872 1 49   
Phosphoglycerate kinase 1  NP_000282 2 49 [10, 29, 130, 132, 134] 












26 962 [10, 131, 134] 
gp330 precursor  AAB41649 16 574 [10, 131] 
Prominin 1  NP_006008 5 290 [10, 129, 131, 134] 
MME Neprilysin CAA30157 5 182   
G protein-coupled receptor (GPRC5C)  CAC00633 4 145 [10, 129, 131] 
Gamma-glutamyltransferase 1 AAA52546 1 122 [10] 
Bile salt export pump  AAD28285 1 120   
Maltase-glucoamylase  NP_004659 3 119 [10] 
NaCl electroneutral Thiazide-sensitive 
cotransporter  
CAA62613 5 111   
Mucin-1  CAA36478 2 111 [10, 129, 131, 134, 
135, 137] 
Orphan G-protein coupled receptor AAF67321 1 66 [10, 131, 134, 135] 
   
(GPRC5B) 
Angiotensin I converting enzyme (peptidyl-
dipeptidase A) 1 
EAW94315 3 94 [10, 130, 131] 
Fructose transporter  AAB60641 2 80   
Napsin A preproprotein  NP_004842 1 80   
Aquaporin 1 AAC16481 1 77 [10, 131] 
Desmoglein-1 precursor  Q02413 1 76   
Solute carrier family 12 member 1 
(Bumetanide-sensitive sodium-(potassium)-
chloride cotransporter 2)  
Q13621 4 55 [10, 131] 
CD26 CAA43118 1 48 [10, 29, 44, 131, 132, 
134] 
Tetraspan TM4SF (Tspan-1)  AAC69714 1 45 [10, 129-131] 






6 679   
Mannan-binding lectin-associated serine 
protease-2 (MASP-2) 
CAA67050 2 389 [10, 131, 138] 
Pro-epidermal growth factor precursor (EGF) P01133 5 223 [10, 131] 
Serum Albumin 2I2Z_A 10 222 [10, 131, 132, 134, 
138, 139] 
Beta-galactosidase related protein precursor AAA35599 5 191   
ACPP acid phosphatase CAA36422 2 106 [10, 131] 
Saposin A 2DOB_A 2 88   
Apolipoprotein J precursor AAA51765 1 60   
Plasma serine protease inhibitor precursor AAA35688 3 58   













7 338 [10, 131] 
Syntenin AAB51246 2 125 [10, 130-135] 
   
Aminopeptidase A AAA35522 6 122 [10, 131] 
Ezrin CAA35893 2 117 [10, 129, 132, 133, 
135, 140] 
CD59 antigen p18-20  NP_000602 1 50   
Beta actin variant  BAD96645 Cytoplasm 
(cytoskeletal) 
6 149 [10, 29, 44, 129, 130, 
132-135, 137, 139-
141] 
Alpha-actin AAA51577 3 68 [10, 130, 132] 
Putative heart protein (PHP)  AAC73009 Lysozyme 2 114   
Cerebroside sulfate activator protein AAA36594 2 105   
Lysosomal pepstatin insensitive protease  AAB80725 1 101   
Cathepsin A EAW75788 2 93 [10, 131] 
Uromodulin  AAH35975 Plasma membrane 
(GPI linked) 
73 4930 [10, 131] 
Dipeptidase 1 (renal)  NP_004404 5 199 [10, 29, 130, 131] 
Histone cluster 1, H2bl  NP_003510 Nucleus 2 63   
Putative MAPK-activating protein PM28 P53990 ER/Golgi 3 190   
Guanine nucleotide binding protein (G 
protein), alpha inhibiting activity 
polypeptide 3  
NP_006487 2 46 [10, 130-132] 
Podocalyxin-like BAB71022 Unclassified 3 106 [10, 131] 
Beta-trace 23.5 kda glycoprotein  AAB24507 1 46   
Apolipoprotein D (apoD)  AAB32200 2 61 [10, 131, 138] 
Table 3.2  All proteins identified by GeLC-MS/MS in the urinary exosomal proteome of a single individual.   
Protein identifications from the GeLC-MS/MS data were made using the MASCOT service and the NCBI database using a 
p<0.05 cut-off.  The subcellular location for each protein was discovered by querying the harvester website 
   
(http://harvester.fzk.de/harvester/).  Instances of a protein previously being identified in exosomes are based on references 
from the exocarta website (http:// exocarta.ludwig.edu.au/). 
 




































Figure 3.5  Sub-cellular location of proteins identified by GeLC-MS/MS. 
In the human urinary exosomes obtained from one individual 76 proteins 
were identified by mass spectrometry (Table 3.2).  These proteins were 














Figure 3.6  Proteins specific to nephron sections. 
The proteins identified in the urinary exosomes of one individual (Table 3.2) 
were analysed using the Harvester website.  Several proteins were found to 












Protein Disease associated 
Renal Diseases 
Uromodulin Hyperuricemic nephropathy 
Medullary cystic disease 2 [142] 
gp330 precursor  renal aminoglycoside accumulation and 
nephrotoxicity [143]  
Donnai-Barrow syndrome [144] 
Pro-epidermal growth factor precursor 
(EGF)  
normocalciuric renal hypomagnesemia 
[145] 
MME Neprilysin membranous glomerulonephritis [146] 
Putative heart protein (PHP)  Farber disease [147, 148] 
NaCl electroneutral Thiazide-sensitive 
cotransporter  
Gitelman syndrome [149] 
carbonic anhydrase II  osteopetrosis and renal tubular acidosis 
[150] 
angiotensin I converting enzyme 
(peptidyl-dipeptidase A) 1  
renal tubule dysgenesis [151], diabetic 
nephropathy [152] 
Solute carrier family 12 member 1 
(Bumetanide-sensitive sodium-
(potassium)-chloride cotransporter 2)  
Bartter syndrome [153] 
Endosomal Diseases 
Beta-galactosidase precursor  GM1-gangliosidosis [154] 
Cerebroside sulfate activator protein Metachromatic Leukodystrophy [155], 
Atypical Gaucher Disease [156] 
Protective protein for beta-galactosidase  galactosialidosis 
Table 3.3  Urinary exosomal proteins identified by GeLC-MS/MS which 
are associated with disease.   
The proteins identified in the urinary exosomes of one individual (Table 3.2) 
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3.3.3. Label-free quantitative mass spectrometry 
With the presence of exosomes in the urine established the opportunity exists 
to explore their proteome as a potential source of biomarkers for disease.  
This opportunity is based on the hypothesis that the proteome of the urinary 
exosomes changes with disease.  As a preliminary step in verifying this 
hypothesis the urinary exosomes of patients with sepsis were compared with 
the urinary exosomes of healthy controls using SDS-PAGE and western blot.  
Using this approach cJun was identified as present in the urinary exosomes 
of all 5 septic patients studied but absent, or below the limit of detection, in 
the urinary exosomes of all 3 healthy controls studied (Figure 3.7). 
 
Biomarker discovery requires the comparison of samples from healthy 
controls and patients with the illness being investigated.  Label-free 
quantitative mass spectrometry is a promising new approach for quantitative 
comparisons.  To investigate its suitability for studying the exosomal 
proteome two experiments using spiked samples were devised.  The first 
experiment used peptide spikes to investigate the accuracy of just the mass 
spectrometry and data analysis steps.  The second experiment used protein 
spikes to also investigate the reproducibility of the protein digestion. 
 
The ratios for 4 of the 5 spiked peptides compared well with the expected 
values (Figure 3.8).  The fifth peptide was poorly detected and the measured 
fold change deviated further from the expected value.  For the spiked 
proteins 4 of the 6 proteins were identified by querying the mass 
spectrometry results against the MASCOT system [119].  The fold changes 
for individual peptides were more variable than for the earlier peptide 
spiking experiment.  Much of this variability was removed by averaging the 
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fold changes across peptides for a protein although the experimentally 
measured fold change remained lower than the expected value for all four 
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Figure 3.7  Western blot for cJun on urinary exosomes from healthy 
controls and septic patients. 





Figure 3.8  Fold change in spiked peptide samples. 
Five peptides were spiked into trypsin digested urinary exosome samples at 
two different concentrations with one being four-fold higher than the other.  
The ion intensities for each of these peptides were then measured using the 
Bruker DataAnalysis software package.  For four of the five peptides two 
charge states could be identified and each is shown by a separate point on 
the graph.  For comparison the fold change in the ion intensities for several 
peptides derived from the uromodulin protein which were not spiked are 
shown. 










Figure 3.9  Fold change in spiked protein samples. 
Six proteins were spiked into urinary exosome samples at two different 
concentrations with one being four-fold higher than the other.  These 
samples were digested with trypsin and the resulting peptides analysed by 
LC-MS/MS.  The peptides originating from the spiked proteins were 
identified using the MASCOT software for four of the proteins (BSA, 
carbonic anhydrase II, lysozyme and phosphorylase) and their ion intensities 
in each sample measured.  For comparison the ion intensities for peptides 
derived from two proteins (uromodulin and galectin 3 binding protein) 
which were not spiked are also shown.  Each point on the graph represents a 
single identified peptide and the horizontal bar represents the mean between 
peptides. 
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3.4. Discussion 
Exosomes have previously been purified from the urine by several groups 
using ultracentrifugation [10, 40].  The protocol used varies between studies, 
perhaps to match the equipment available [116].  Based on the protocols of 
other groups and using the equipment available in our laboratory we have 
established a protocol for the purification of exosomes.  Using western blot 
the exosomal markers TSG101, flotillin 1 and CD24 have been shown to be 
enriched in the ultracentrifuge pellet.  Using isopycnic centrifugation we 
have established that these three markers are present on particles with a 
density of 1.12-1.16 g.cm-3 which matches very closely with previous reports 
for exosomes [116].  Finally, using transmission electron microscopy we have 
directly visualised the particles in the ultracentrifuge pellet.  Previous reports 
have described exosomes as cup-shaped in appearance and 20-100 nm in 
diameter [116] with more recent reports suggesting exosomes are 
predominantly at the lower end of this range [10, 40].  We were able to 
identify structures fitting this description.  Taken with the other results the 
direct visualisation of exosomes means we can be confident in the isolation 
protocol.  With the protocol established it should be directly transferable to 
other biofluids. 
 
Using GeLC-MS/MS 76 proteins were identified from the urinary exosomal 
proteome.  Only 13% of the identified proteins were known to be 
extracellular.  Contamination of the exosomal preparation with protein from 
the soluble proteome is a potential concern but the high percentage of 
plasma membrane and cytoplasmic proteins, 30% and 42% respectively, in 
comparison to the much lower number of the extracellular proteins suggests 
this is not a significant problem.  Searching the OMIM database for the 76 
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identified proteins revealed 12 which were linked to disease.  Furthermore 
several of the proteins were known to be specific or enriched in certain 
sections of the nephron (for example, the presence of aquaporin 2 is 
consistent with exosome release from the collecting duct) suggesting that the 
exosomal preparation included exosomes which had been released from 
these regions of the nephron.  These observations taken together suggest that 
the urinary exosomes represent a rich source of information, including 
biomarkers, on the entire length of the nephron, from the glomerulus 
through to the collecting duct. 
 
Our interest in the exosomes as a potential source of biomarkers is based on 
the hypothesis that the proteome of the exosomes will change in response to 
the pathophysiological state of their cells of origin.  Discovery-based 
proteomics should enable an unbiased search of the exosomal proteome for 
proteins which change between conditions but the technique is time 
consuming and costly.  As a preliminary step a hypothesis-driven approach 
was used to identify changes in proteins we predict might change with 
sepsis.  Transcription factors have previously been identified as potential 
biomarker candidates in exosomes [157].  Sepsis is an inflammatory 
condition so we investigated the inflammatory transcription factor cJun.  In 
patients with sepsis we were able to detect cJun in their urinary exosomes 
but we could not detect cJun in the urinary exosomes purified from the urine 
of healthy controls.  It is necessary to note several limitations with this small 
experiment.  Firstly, the number of controls and patients was small, three 
healthy controls and five patients.  Secondly, the two groups are not well 
matched.  The healthy controls are considerably younger and are not hospital 
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patients.  Despite these limitations this result suggests that a large scale 
discovery driven shotgun proteomics study should yield results. 
 
The GeLC-MS/MS experiment could have been significantly expanded, by 
further fractionation of the gel and repeating the tandem mass spectrometry 
analysis, and yet despite the small scale still provided a wealth of 
information.  Although improvements could be made to the existing protocol 
the search for biomarkers would be enhanced by quantitative data.  A 
number of approaches for quantitative mass spectrometry have been 
developed utilising labels [158] but these involve adding processing steps 
which slow down the analysis, increase the cost and increase the errors.  We 
decided instead to use a label-free approach because this potentially avoids 
many of the problems.  Label-free quantitative mass spectrometry has only 
relatively recently become viable with improvements in the mass 
spectrometers and data analysis and as such the limitations of the technique 
are not as well understood [65, 159].  For this reason we began by 
investigating the accuracy of label-free quantitative mass spectrometry on 
spiked samples.  Using peptide spikes allows the analysis of just the mass 
spectrometry and subsequent data analysis and in this experiment these 
steps did perform well.  For four of the five peptides two ions could be 
detected and the experimentally measured fold change agreed closely with 
the expected value.  The fifth peptide was poorly detected and the one ion 
which was detected deviated further from the expected fold change.  Using 
protein spikes the accuracy of the entire experiment could be investigated.  
There was greater variability as would be expected with extra processing 
steps.  Reducing the variability will be desirable but even with the level of 
variability seen in this experiment label-free quantitative mass spectrometry 
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could have potential as an initial screening tool.  For all four proteins the fold 
change was underreported.  This could potentially be due to reduced 
digestion and/or recovery of peptides from the sample spiked with the larger 
amount of protein.  Switching from in-gel to in-solution digestion should 
reduce this effect and also reduce the variability. 
 
Using western blotting for exosomal markers, density measurement by 
isopycnic centrifugation and direct visualisation by TEM we have confirmed 
that human urine contains exosomes and have demonstrated that our 
isolation protocol effectively isolates exosomes from the urine.  Using GeLC-
MS/MS we have begun to characterise the urinary proteome.  We have 
demonstrated that the presence of cJun within the exosomes changes with 
sepsis and have evaluated the ability of label-free mass spectrometry to 
measure proteome-wide changes in the urinary exosomes. 
 











4. Characterisation of the cortical collecting duct cell 
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4.1. Introduction 
In chapter three techniques were developed to confirm the presence of 
exosomes in human urine [10, 40, 131]. These exosomes contain aquaporin 
(AQP) 2 indicating that, in vivo, exosomes are released from the collecting 
duct [10, 40, 131].   
 
There is some evidence that the proteome of the kidney-derived exosome 
changes with cell stimulation or injury.  For example, Zhou et al have 
demonstrated a change in the urinary exosomal proteome with disease.  In a 
rat model of cisplatin induced acute kidney injury the exosomal protein 
fetuin A was demonstrated to increase with injury [160].  Although evidence 
is accumulating that the proteome does change with stimuli we do not fully 
understand the biological significance of such changes.  Our understanding 
of the role of exosomes within the immune system is significantly more 
advanced, with a number of studies demonstrating that exosomes can 
transfer information between cells [1, 2, 19]. Study of cell culture models 
relevant to the kidney should increase our understanding of how the protein 
composition of the exosome changes with cell stimulation and allow us to 
determine if exosomes can transfer information between cells.   
 
The kidney is a heterogeneous organ comprising different cell types each of 
which may respond differently to stimulation and the presence of exosomes.  
In choosing a cell line to study two competing factors were considered.  
Firstly, the estimated contribution of the nephron section to the pool of 
exosomes in human urine and, secondly, the exposure of the nephron section 
to exosomes in vivo. An established and characterised murine cortical 
collecting duct (mCCD) cell line [118, 161] was chosen because  human 
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urinary exosomes have been repeatedly demonstrated to contain collecting 
duct proteins and, as the collecting duct is ‘downstream’ in terms of flow 
through the nephron, it is potentially exposed to exosomes from a range of 
cell types.   
 
Our aim was to establish the mCCD cell line as a model for the study of 
exosomes.  This model would be used to study the release of exosomes.  The 
effect of exosomes on this cell line could then also be investigated. 
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4.2. Methods 
The mCCD cells were raised from frozen stocks maintained within the 
laboratory following the generous gift of the cell line by Hans-Peter 
Gaeggeler, University of Lausanne, Switzerland [118].  The cells were 
routinely passaged using the protocol described in Chapter 2.10.2.  The 
standard media (Chapter 2.10.1.) for this cell line includes 2% foetal calf 
serum (FCS).  In early experiments it was demonstrated that the FCS 
contained exosomes which interfered with the detection of exosome release 
from the cells.  To overcome this, exosome-depleted media was prepared by 
ultracentrifugation and filtration of 20% FCS as described in Chapter 2.10.3. 
and based on previously published protocols [116]. 
 
The exosomes released from the cells were purified from the media using the 
protocol previously established for the urine (Chapter 2.1.2 and 2.2.).  The 
presence of exosomes was confirmed using SDS-PAGE (Chapter 2.3.1.), 
western blot (Chapter 2.4.), isopycnic centrifugation (Chapter 2.5.) and 
transmission electron microscopy (TEM; chapter 2.6.1.).  The Thermo gel 
system was used for the SDS-PAGE. 
 
The cells were stimulated with ionomycin, cisplatin and desmopressin 
(dDAVP) and as described in Chapter 2.10.5.  Using FACS the effect of 
cisplatin and dDAVP on cellular apoptosis and necrosis was investigated.  
The protocol for FACS is outlined in Chapter 2.10.4. 
 
The biological role of exosomes was investigated by collecting exosomes 
from mCCD cells stimulated with 3.16 ng/ml dDAVP for 96 hours and then 
applying them back on to unstimulated mCCD cells as described in Chapter 
2.10.6. 
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4.3. Results 
4.3.1. Exosome detection in mCCD cell conditioned media 
Ultracentrifugation of mCCD cell conditioned media forms a pellet which 
suggests that the mCCD cells release low density membrane vesicles.  To 
establish whether the low density membrane vesicles released by the mCCD 
cells are exosomes the presence of two exosomal markers in the pellet was 
investigated.  Ultracentrifugation of 20 ml of media obtained following a 48 
hour incubation with a confluent T75 tissue culture flask yielded sufficient 
material for one or two separations by SDS-PAGE and subsequent western 
blot. 
 
Flotillin 1 is thought to be present at the site of exosome formation and is 
often present in exosomes [1].  TSG101 is a component of the ESCRT-I 
complex and is directly involved in exosome formation.  Flotillin 1 and 
TSG101 were both present in the ultracentrifuge pellet but not the 
supernatant (Figure 4.1). 
 
The density of the particles containing flotillin 1 and TSG101 was determined 
using isopycnic centrifugation on a sucrose step gradient.  Six fractions were 
collected from the gradient (Figure 4.2).  The exosomal markers flotillin 1 and 
TSG101 together with AQP2 were predominantly localised to fractions 3 and 
4 which corresponded to a density of 1.10 - 1.15 g.cm-3. 
 
The particles in the ultracentrifugation pellet were directly visualised using 
TEM.  Exosomes have previously been shown to vary in size from 20-100 nm 
and have a cup-shaped appearance.  Structures matching this description in 
size and appearance could be easily identified (Figure 4.3). 








Figure 4.1  Western blot for exosomal markers on the ultracentrifugation 
pellet and supernatant from cultured collecting duct cells.   
Both the exosomal markers A) flotillin 1 and B) TSG101 are enriched in the 










Figure 4.2  Western blot for AQP2, TSG101 and flotillin 1 on density 
fractions obtained following isopycnic centrifugation of dDAVP and 
ionomycin stimulated cell conditioned media.   
A)  Following stimulation with dDAVP AQP2, TSG101 and flotillin 1 are all 
present on particles with a density of 1.10-1.15 g.cm-3 which is consistent with 
previous reports for exosomes.  This distribution has been consistently 
observed over five replicates for TSG101 and flotillin 1 and three replicates 
for AQP2.  The exosomal markers are present in the range 1.10-1.18 g.cm-3 for 
all repeats.  B) Flotillin 1, although concentrated at a density of 1.15 g.cm-3 is 
present throughout the gradient following isopycnic centrifugation of 
exosomes derived from ionomycin stimulated cells. 
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Figure 4.3  Transmission electron micrograph of exosomes.   
The resuspended ultracentrifuge pellet was incubated and fixed on a formvar 
coated gold mesh grid which was then negatively stained with uranyl acetate 
and embedded with methyl cellulose.  Under these conditions exosomes 
have been found to be 20-100 nm in diameter and have a cup-shaped 




Figure 4.4  Western blot for the exosomal marker TSG101 on 
unconditioned media and unstimulated and ionomycin stimulated mCCD 
cell conditioned media.   
TSG101 is increased with ionomycin treatment indicating exosome release. 
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4.3.2. Exosome release in response to stimuli 
Release of exosomes has been shown to vary in response to a variety of 
different stimuli.  Ionomycin is a calcium ionophore that facilitates the influx 
of calcium into the cell.  Two hours after incubation with ionomycin there 
was more TSG101 present in the ultracentrifuge pellet than following 24 
hours incubation without ionomycin (Figure 4.4).   
 
Ionomycin is an artificial stimulus which the mCCD cells would not 
encounter under physiological conditions.  Two factors were identified as 
models of physiological and toxicological insults.  Desmopressin (dDAVP), a 
synthetic vasopressin analog, was chosen as the physiological stimuli.  
Stimulation with dDAVP should cause the upregulation of AQP2 in the cell 
line [161].  Cisplatin was chosen as the toxicological insult.  Exosomal fetuin 
A has previously been identified as a potential biomarker in a rat model of 
cisplatin-induced acute kidney injury [160].   
 
If the cells become apoptotic or necrotic they may release non-exosomal 
particles which could interfere with our study [116].  For example the 
calcium ionophore ionomycin induces a increase in the exosomal marker 
TSG101 in the ultracentrifuge pellet but the particles present spread 
throughout a gradient during isopycnic centrifugation (Figure 4.2B) 
indicating the presence of particles other than exosomes.  To avoid this a 
concentration for dDAVP and cisplatin was determined which would not 
cause significant apoptosis or necrosis.  In previous studies mCCD cells had 
been stimulated with dDAVP at a concentration of 1 ng/ml [161] without 
detrimental effect.  Stimulation with 3.16 ng/ml dDAVP had no effect on cell 
necrosis but increased the proportion of apoptotic cells (Figure 4.5A; 
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p=0.014). However, the percentage of apoptotic cells was still less than 1% in 
all experiments.  Stimulation with cisplatin at a concentration of 10 µg/ml 
caused a more than two-fold increase in the proportion of necrotic cells 
(8.2±0.8% compared to 3.6±0.5%, p=0.008) but no change in the proportion of 
apoptotic cells (2.3±1.6% compared to 1.7±1.0%, Figure 4.5B). Cisplatin at a 
concentration of 3.16 µg/ml did not induce significant cell death. Based on 
these results, the maximum concentration in subsequent experiments was set 


































Figure 4.5  Change in the proportion of apoptotic and necrotic cells 
following stimulation. 
Cells were stimulated with A) dDAVP and B) cisplatin.  Cells were stained 
with Annexin V-fluorescein and propidium iodide and indicators of 
apoptosis and necrosis respectively and then analysed by FACS.  Bars are 
means of 3 experiments. Error bars represent SEM.  * p < 0.05, ** p < 0.01.  C)  
A dot plot showing one sample analysed by FACS.  Cells in the lower right, 
upper left and upper right quadrants are considered to be apoptotic, primary 
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The mCCD cells were stimulated with dDAVP for 96 hours with the media 
collected and replaced at 48 hours.  Stimulation of the mCCD cells with 
dDAVP did not alter exosome release as measured by flotillin 1 in the 
ultracentrifuge pellet after 48 hours or 96 hours.  AQP2 was not detected in 
the exosomes released by the cells after 48 hours.  At 96 hours AQP2 was 
detected in the exosomes from the stimulated cells but not the unstimulated 
cells (Figure 4.6, 4.7).  This appeared to be a dose dependent increase which 




























Figure 4.6  Western blot for AQP2, flotillin 1 and TSG101 on exosomes and 
cell extracts from dDAVP stimulated mCCD cells.   
Cell extracts were collected at 96 hours.  AQP2 released in exosomes is 
increased by dDAVP stimulation at 96 hours but not at 48 hours.  AQP2 is 
also upregulated in the cell extracts which were collected at 96 hours.  The 
release of exosomes as measured by flotillin 1 and TSG101 does not change.  
 










Figure 4.7  Semi-quantitative densitometry on the bands obtained by 
western blot on exosomes and cell extracts from dDAVP stimulated cells. 
Densitometry on bands for A) AQP2, B) TSG101 and C) flotillin 1.  Cell 
extracts were collected at 96 hours.  AQP2 released in exosomes is increased 
by dDAVP stimulation at 96 hours but not at 48 hours.  AQP2 is also 
upregulated in the cell extracts which were collected at 96 hours.  The release 
of exosomes as measured by flotillin 1 and TSG101 does not change.  * p < 



















Figure 4.8  Correlation between band intensities for AQP2 in the exosomes 
and cell extracts of dDAVP stimulated cells. 
Band intensities were measured by semi-quantitative densitometry on 
western blots for AQP2 in the cells and the exosomes following stimulation 
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To investigate whether AQP2 was present in the cells at 48 hours a second 
experiment was conducted with the mCCD cells stimulated with dDAVP 
and then collected at 48 hours.  The exosomal markers TSG101 and flotillin 1 
are present in the cells at 48 hours at approximately equivalent levels to 96 
hours.  AQP2 is only faintly detected even at the highest concentration of 
dDAVP (Figure 4.9). 
 
To confirm that AQP2 is present in exosomes the constituents of the 
ultracentrifuge pellet were separated on a density gradient using isopycnic 
centrifugation.  AQP2 co-localised with the exosomal markers TSG101 and 
flotillin 1 in fractions 3 and 4 (Figure 4.2).  This corresponded to a density of 
1.10 – 1.15 g.cm-3 which would be expected for exosomes. 
 
Stimulation of the mCCD cells with cisplatin did not alter exosome release as 
measured by flotillin 1 in the ultracentrifuge pellet.  Fetuin A was present in 
the exosomes released from the unstimulated cells and did not appear to 
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Figure 4.9  Western blot for AQP2, TSG101 and flotillin 1 on cell extracts 
from mCCD cells stimulated with dDAVP for 48 hours.   
AQP2 is only faintly detected in experiment 3 at the highest dose of dDAVP.  
The exosomal markers TSG101 and flotillin 1 do not change. 
 
 
Figure 4.10  Western blot for fetuin A and flotillin 1 on exosomes from 
cisplatin stimulated mCCD cells.   
Fetuin A is present at all doses of cisplatin and does not increase with dose.  
The release of exosomes as measured by flotillin 1 also does not change.  
Presented are 3 independent biological replicates. 








Figure 4.11  Semi-quantitative densitometry on bands obtained by western 
blot for A) fetuin A and B) flotillin 1 on exosomes from cisplatin 
stimulated mCCD cells.   
Fold changes are on the adjusted volume with respect to the control.  Fold 
changes were used to prevent global changes in band density between 
repeats obscuring any dose dependent change.  Fetuin A is present at all 
doses of cisplatin and does not increase with dose.  The release of exosomes 
as measured by flotillin 1 also does not change. n=3. 
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4.3.3. Biological activity of released exosomes 
Exosomes can act as intercellular messengers by interacting with the cell 
surface and/or by being absorbed by cells.  To investigate exosome-cell 
interaction we collected exosomes from cells stimulated with dDAVP for 96 
hours and then applied these exosomes back on to mCCD cells.  After a 48 
hour incubation the presence of AQP2 in the mCCD cells was quantified by 
western blot and semi-quantitative densitometry (Figure 4.12, 4.13).  AQP2 in 
the cells stimulated with exosomes from dDAVP stimulated cells was 
increased (p=0.017).  As controls the increase in AQP2 in cells following 
dDAVP stimulation was quantified (p=0.040) and the presence of AQP2 in 
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Figure 4.12  Western blot for AQP2 on cell lysates following incubation 
with AQP2 containing exosomes. 
AQP2 is present in the cells extracts following incubation with AQP2 
containing exosomes or with dDAVP. 
 
 
Figure 4.13  Semi-quantitative densitometry on bands obtained by western 
blot for AQP2 following stimulation of mCCD cells with AQP2 containing 
exosomes.  
* p<0.05, n=4. 
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4.4. Discussion 
Exosomes have been demonstrated to be present in human and rodent urine 
[10, 40, 51, 110, 131, 160].  The complexity of in vivo studies in humans 
presents significant challenges in understanding the role of urinary exosomes 
in health and disease.  Although problems remain in translating results from 
in vitro models back to the whole organism they are a useful approach to 
simplifying an experimental system.  This approach has been applied to the 
study of exosomes with considerable success [18].  Published articles suggest 
that exosomes are released, to a greater or lesser extent, by all cells.  The in 
vitro model documented here used a cortical collecting duct cell line derived 
from the kidney of the mouse [118].  Using western blot, isopycnic 
centrifugation and transmission electron microscopy we have shown that 
this cell line does release exosomes.   
 
In previous studies ionomycin has been used to induce exosome release [40, 
162-164]. Ionomycin is a calcium ionophore which facilitates the influx of 
calcium into the cell.  Ordinarily the concentration of calcium in the cytosol is 
low.  An increase in the cytosolic calcium concentration is a signal for a 
variety of processes including secretion of the cell contents.  In the mCCD 
cells ionomycin caused a rapid release of exosomes from the cells into the 
media. 
 
Ionomycin is a generic stimulus of exosome release which will work for 
many cell types.  Focusing more specifically on the mCCD cells two 
hypotheses surrounding physiological and toxicological stimuli were 
investigated.  Exosomes were first suggested as a possible explanation for the 
presence of the membrane protein AQP2 in the urine as early as 1995 [165].  
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The group which established the mCCD cell line also demonstrated that 
AQP2 was increased in these cells following incubation with dDAVP [161].  
The data presented in this chapter demonstrate that AQP2 is increased in the 
exosomes following stimulation of the cells with dDAVP.  Using isopycnic 
centrifugation and western blot we confirmed that the released AQP2 was 
present in exosomes. 
 
The presence of AQP2 in the exosomes closely mirrored the presence of 
AQP2 in the cells.  AQP2 was present in neither the exosomes nor the cells 
prior to stimulation and then present in both following stimulation for 96 
hours.  The increase in AQP2 concentration in the exosomes faithfully 
reflected the increase in cellular AQP2. 
 
Exosomal fetuin A has been identified as a potential biomarker of cisplatin-
induced acute kidney injury [160].  In our in vitro model stimulation with 
cisplatin did not alter the presence of fetuin A in the exosomes.  The lack in 
response could be explained by other sections of the nephron being 
responsible for the increase seen in the rat model.  Fetuin A is widely 
expressed and is present in blood plasma.  Therefore, the increase in fetuin A 
could be due to leakage of fetuin A from the plasma into the urine and 
subsequent contamination of the exosomal preparation by the soluble 
proteome of the urine. 
 
The two models investigated here support the hypothesis that changes in the 
exosomes reflect changes in the cells.  Although fetuin A did not change in 
the exosomes as we had predicted from in vivo findings, fetuin A also failed 
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to change in the cells.  AQP2 in the exosomes increased with stimulation but 
only after 96 hours which was consistent with the response seen in the cells. 
 
In addition to our interest in exosomes as a potential source of biomarkers 
exosomes have biological activity in a variety of systems.  Exosomes can alter 
cellular activity by interaction of receptors following contact with the cell 
surface or uptake of the exosomes and transfer of the exosomal contents to 
the cell.  Incubating AQP2 containing exosomes with cells results in 
increased AQP2 in the cell lysate.  The protocol used would not differentiate 
between adsorption of exosomes onto the cell surface and uptake of 
exosomes absorption of exosomes into the cells.  These results establish that 
the exosomes interact with the cells but further work will be needed to 
characterise the interaction. 
 
The urinary exosomes have been hypothesised to reflect the state of the cells 
in the kidneys but there has been little robust evidence to support this.  
Packaging of intracellular proteins into intralumenal vesicles occurs via 
several pathways, including targeting of monoubiquitinated proteins and 
association with lipid rafts.  It remains unclear what impact these different 
pathways will have on the hypothesised relationship.  Despite this 
uncertainty we show here that a change in the presence of a protein, AQP2, 
in the exosomes does appear to reflect a change in the presence of that 
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5.1. Introduction 
Neurological diseases produce a high burden of morbidity and mortality 
[105, 166]. This burden will increase substantially in the decades ahead, 
particularly for conditions associated with aging [106].  Early and accurate 
diagnosis is essential to ensure that patients receive optimal care.  For 
Alzheimer’s disease, the prevalence of which is increasing rapidly due to its 
association with aging [106], early and accurate diagnosis has only begun to 
be possible in the last few years.  As recently as 2000, the diagnostic criteria 
for Alzheimer’s disease involved excluding all other recognised types of 
dementia rather than the utilisation of any test specific for Alzheimer’s 
disease [167].  The diagnosis now involves structural and molecular 
neuroimaging and biomarker detection in the cerebrospinal fluid.  Despite 
the progress that has been made there are still aspects of the disease which 
remain poorly understood and monitoring disease progression is difficult 
[107]. 
 
The material with the greatest potential for biomarker discovery in the 
context of neurological disorders is brain tissue.  Although tissue may be 
available post mortem the disease in such samples will likely be highly 
progressed and may not reflect the early stages of the disease.  Obtaining a 
tissue sample from the brain will involve significant safety risks and is 
therefore often impractical.  The cerebrospinal fluid is in constant contact 
with the brain tissue and as such is likely to be the next best option. 
Although preferable to the blood the CSF is not without its problems; the 
volume obtainable is less than with urine and the protein content is lower 
than blood, giving less potential material to study.  The protein that is 
present is largely the same high abundant proteins present in the circulation 
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[168, 169].  As with other biofluids, exosomes offer one option to reduce the 
concentration of the high abundance proteins and focus on the lower 
abundance, and assumed more biologically interesting, proteins.  As yet 
exosomes have not been identified in human CSF.  There is evidence to 
suggest that human CSF will contain exosomes; a variety of cell types present 
in the central nervous system have been shown to release exosomes in vitro 
[34, 35, 164, 170] and exosomes have been identified in the CSF of sheep [36].  
Rat cortical primary cultures have been demonstrated to release exosomes 
[170] and the prion proteins, PrPC (cellular) and PrPSc (scrapie), when 
expressed in a glial cell line [34] or a mouse neuroblastoma cell line [35], are 
released in association with exosomes.  Furthermore, exosomes may have an 
important pathophysiological role in Alzheimer’s disease.  Cleavage of the 
amyloid precursor protein by the enzyme β-secretase occurs in a subset of 
endosomes and a fraction of the Aβ protein is released into the extracellular 
milieu in association with exosomes [32, 171].  Importantly, exosomal 
markers are enriched in amyloid plaques from the brains of mice [172] and 
the post-mortem brains of patients with Alzheimer’s disease [32]. 
 
Although there is circumstantial evidence to suggest that human CSF will 
contain exosomes, to date there is no published report confirming that they 
are present.  Using the exosome purification protocol established in the urine 
(chapter 3) the presence of exosomes in human CSF has been investigated. 
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5.2. Methods 
CSF was collected from five patients undergoing thoraco-abdominal aortic 
aneurysm repair with full ethical approval (REC reference number 
08/S1102/59).  These patients routinely have a CSF drain inserted as a 
standard aspect of their clinical management [114].  The CSF was processed 
using the protocol developed for the urine (Chapter 2.1.3. and 2.2.).  Briefly, 
the CSF was centrifuged at 15,000 x g to pellet cell debris and any large 
membrane fragments and then the supernatant centrifuged at 200,000 x g to 
pellet the exosomes. Protease inhibitors and preservative was added to the 
CSF prior to centrifugation.  The protein content of the exosomal preparation 
was measured using the BCA assay following the manufacturer’s 
instructions.  The protocol used to determine whether exosomes were 
present followed the approach used in the urine and cell culture media.  
SDS-PAGE and western blot were used to detect exosomal markers in the 
ultracentrifuge pellet (Chapter 2.3.1 and 4.).  The membrane was also stained 
with Ponceau S solution to visualise the soluble and exosomal proteomes 
(Chapter 2.4.2.).  SDS-PAGE was performed using the Thermo gel system as 
described in Chapter 2.  Isopycnic centrifugation (Chapter 2.5.) and western 
blot were used to determine the density of the particles containing the 
exosomal markers.  Transmission electron microscopy (TEM) was used to 
directly visualise the particles present in the ultracentrifuge pellet (Chapter 
2.6.1.) and immuno-TEM used to identify flotillin 1 containing particles 
(Chapter 2.6.2.). 
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5.3. Results 
Ultracentrifugation of human CSF formed a pellet suggesting that there was 
a low density membrane fraction present in the CSF.  Although there is 
variation between samples all five contained protein (Figure 5.1).  Across the 
five samples the average was 3.45±0.59 µg protein for each millilitre of CSF 
processed.  This was not significantly different compared to 5.17±1.20 µg 
protein per millilitre in the urine (p=0.28, n=5 for the CSF and n=8 for the 
urine).  SDS-PAGE was performed on a sample of the ultracentrifuge pellet 
and the whole CSF.  The protein was transferred to a PVDF membrane and 
then stained with Ponceau S stain (Figure 5.2).  There is some overlap in the 
principal bands but there were bands unique to the ultracentrifuge pellet 
sample suggesting that this is a unique proteome distinct from the soluble 
proteome.  To investigate whether this proteome was exosomal in origin the 






















Figure 5.1  Exosomal protein per millilitre of CSF.  
The protein in the ultracentrifugation pellet is expressed per ml of CSF.  


























Figure 5.2  SDS-PAGE of the whole human CSF and the ultracentrifuge 
pellet. 
The molecular weight of the main bands in the pellet and whole CSF are 
different suggesting the proteome of the pellet is different to the soluble 









Flotillin 1 is associated with lipid rafts which frequently act as the location 
for exosomal formation and as such flotillin 1 is widely reported to be 
present in exosomes [1].  TSG101 is a component of the ESCRT-I complex and 
is involved in the formation of exosomes.  TSG101 is also widely reported to 
be an exosomal marker [173].  Western blot for flotillin 1 and TSG101 on the 
ultracentrifuge pellet and supernatant showed enrichment of both proteins 
in the pellet (Figure 5.3).   
The density of the flotillin 1 and TSG101 positive particles was determined 
using isopycnic centrifugation on a sucrose step gradient.  Six fractions were 
collected from the gradient and a western blot for flotillin 1 was performed to 
determine its location (Figure 5.4).  Flotillin 1 localised to fractions 3 and 4 
which corresponds to a density of 1.10-1.14 g.cm-3. 
 
Using transmission electron microscopy (TEM) the particles in the 
ultracentrifuge pellet were directly visualised.  In previous studies exosomes 
have been shown to vary in size from 20 to 100 nm and have a cup-shaped 
appearance.  TEM revealed a number of structures of the correct size and 
appearance including those highlighted in the electrograph (Figure 5.5).  In 
contrast to other biofluids many of the structures with the characteristic 
shape for exosomes were at the top of the size range, in the region of 100 nm.  
As a final step in establishing the presence of exosomes, the TEM grid was 
incubated with an anti-flotillin 1 antibody followed by a secondary antibody 
tagged with a 10 nm gold nanoparticle which shows up as a dark dot when 
viewed under the transmission electron microscope.  This demonstrated cup-
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shaped structures of the characteristic size for exosomes showing bound gold 
nanoparticles (Figure 5.6).  When the flotillin 1 antibody was replaced with 
an isotype control antibody although structures of the characteristic size and 






























Figure 5.3 Western blot for flotillin 1 and TSG101 on the 
ultracentrifugation pellet (P) and supernatant (S) for three samples of CSF.   






Figure 5.4  Western blot for flotillin 1 and TSG101 on fractions obtained 
following isopycnic centrifugation of the resuspended ultracentrifuge 
pellet.  
The exosomal markers are present in fractions corresponding to a density of 1.10-
1.14 g.cm-3 which is consistent with previous reports for exosomes.  This distribution 
has been consistently observed over four replicates.  The exosomal markers are 
present in the range 1.10-1.18 g.cm-3 for all repeats. 
 
 









Figure 5.5  Transmission electron micrograph of exosomes derived from 
human CSF.  
Exosomes have previously been described as 20-100 nm in diameter and cup-
shaped in appearance.  Arrows highlight several structures with size and 


















Figure 5.6  Transmission electron micrograph of exosomes 
immunolabelled for flotillin 1.  
Exosomes have previously been described as 20-100 nm in diameter and cup-
shaped in appearance.  Flotillin 1 is a known exosomal marker.  An arrow 
highlights an exosome displaying two gold nanoparticles consistent with an 
exosome containing flotillin 1.   
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5.4. Discussion 
Release of exosomes from a variety of different neuronal cell lines has been 
demonstrated by several research groups.  In addition to demonstrating their 
release [170] these groups have reported that the exosomes possess biological 
activity, for example in the context of Alzheimer’s disease [32, 171], 
Parkinson’s disease [164] and prion diseases [33-35].  In addition to the in 
vitro studies there has been one study which has found exosomes in the CSF 
of sheep [36].  Despite the potential importance of exosomes in the context of 
the central nervous system (CNS) and neurological diseases, no group has 
reported their presence in human CSF.  In the present study we have 
demonstrated that exosomes are present in, and can be isolated from, the 
CSF of humans.  We have identified exosomes in human CSF using the same 
approach used for the urine (Chapter 3).  The evidence takes three forms: 1) 
proteins widely documented to be present within exosomes are enriched in 
the ultracentrifugation pellet in comparison with the supernatant; 2) 
following separation of the ultracentrifugation pellet based on density, the 
markers localise to a density range which is consistent with these proteins 
being contained in exosomes; 3) direct visualisation of the resupended 
membrane vesicles from the ultracentrifugation pellet revealed the presence 
of structures matching in size and shape those seen in previous studies of 
exosomes.  In a further experiment these structures were shown to contain 
the exosomal marker flotillin 1. 
 
Exosomes isolated from the CSF are a potentially valuable source of 
biomarkers for neurological disease.  Based on observations in other, 
particularly in vitro, systems it is reasonable to hypothesize that the 
exosomes in the CSF will reflect the state of the cells in the CNS.  Although 
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not as common as taking a blood or urine sample, obtaining a CSF sample is 
still a relatively routine procedure and a robust panel of biomarkers would 
be advantageous in the diagnosis and treatment of a variety of neurological 
diseases [107].  The treatments available for the most significant neurological 
diseases focus on managing the symptoms and delaying progression of the 
disease [107, 174].  Early diagnosis will enable the commencement of 
treatment while the clinical burden of disease is still low.  Furthermore, there 
is some evidence from animal models to suggest that therapies will be more 
effective when begun early in the progression of the disease [175-177].  
Although some treatments are available there is still a significant need for 
more effective interventions [178, 179].  The effectiveness of potential new 
therapies will be assessed in clinical trials against a variety of cognitive and 
functional primary end points [174].  Unfortunately the outcome of such tests 
is impacted by factors other than disease pathology which may confound the 
results.  A panel of biomarkers might provide a more accurate indication of 
the effectiveness of an intervention or identify a subpopulation of the trial 
group with enhanced benefit.   
 
Several groups have presented evidence which suggests that beyond their 
potential utility as a source of biomarkers exosomes may also have a 
biological role in a number of neurological diseases.  It has previously been 
shown that alix [32] and flotillin 1 [172], both markers of exosomes, are 
present in the amyloid plaques which are central to the progression of 
Alzheimer’s disease. This finding is consistent with exosomes, including 
those present in the CSF, being involved in plaque formation.  In vitro cells 
release prions in association with exosomes and these exosomes are sufficient 
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to mediate infectivity [33-35]. CSF-derived exosomes from sheep have also 
been shown to possess prions [36]. 
 
Although our findings suggest that CSF-derived exosomes have potential in 
diagnosing and monitoring neurological disease there are limitations with 
this study.  Firstly, the samples used were obtained from five patients who 
received a CSF drain as part of standard clinical management for a thoraco-
abdominal aortic aneurysm repair operation [114] and to our knowledge 
none of these patients suffer from any neurological disease. However, 
exosomes are likely to be present in disease as well as health. Secondly, it 
remains to be determined whether the exosomes in the CSF represent a 
mixed population originating from multiple brain regions and cell types, or 
they are from only a discrete cell type or anatomical site.  If the latter is true 
then it does not necessarily follow that the discrete region or sub-type of cells 
will overlap with the sub-regions or sub-types involved in a particular 
neurological disease. Thirdly, because the CSF drain is in place for a 
prolonged period of time as part of the thoraco-abdominal aortic aneurysm 
repair surgery a considerable volume of CSF was available for analysis.  This 
was important for the success of this study as the exosomes in the CSF are 
more dilute than in the urine.  For the CSF exosomes to be used as a source of 
biomarkers it will be first necessary to establish that they can be purified in a 
useful quantity from a volume more suitable to a diagnostic test. 
 
In summary, this chapter demonstrates that human CSF contains exosomes 
whose proteome will be investigated in the next chapter.  
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6.1. Introduction 
 
There is a high burden of morbidity and mortality associated with 
neurological diseases [105, 166]. In part this is due to a lack of treatments 
capable of reversing the underlying disease processes.  The currently 
available treatments focus on alleviating the symptoms and delaying disease 
progression [167].  Early diagnosis, which will depend on robust biomarkers, 
is therefore important in reducing the burden of disease.  Biomarkers may 
also be a valuable source of mechanistic information on disease state 
allowing the subdivision of a patient population and the subsequent 
targeting of clinical trials and therapies to those patients able to most benefit. 
 
The development of biomarkers is complicated by the difficulty in analysing 
the central nervous system (CNS).  The blood-brain barrier limits passage of 
proteins from the CNS into the circulation which complicates the study of the 
plasma as a source of biomarkers.  Advanced imaging techniques have 
transformed the identification and quantification of CNS disease [180], but 
these approaches are expensive and time consuming.  The identification of a 
protein biomarker in the cerebrospinal fluid (CSF) would potentially offer a 
more expedient diagnosis at reduced cost and disruption to the patient.  
 
In the previous chapter we demonstrated that exosomes were present in 
human CSF.  We hypothesise that the exosomes within the CSF will provide 
information on the state of the CNS, as demonstrated with urinary exosomes 
and kidney disease.  There is in vitro evidence to support this hypothesis.  
Studies utilising neuronal and glial cell lines have demonstrated 
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pathophysiological roles for exosomes in Alzheimer’s disease [32, 171], 
Parkinson’s disease [164] and prion diseases [34, 35].  
 
In chapter 3 GeLC-MS/MS identified a number of proteins in human urinary 
exosomes.  Separation of a sample in two dimensions, firstly proteins by 
denaturing gel electrophoresis and then peptides by liquid chromatography, 
sufficiently reduced the complexity of the peptide mixture entering the mass 
spectrometer to allow the analysis of a large variety of different peptides.  
Analysis of the peptides by tandem mass spectrometry then enabled the 
accurate identification of many of these peptides and their parent proteins.   
 
GeLC-MS/MS is well suited to identifying many proteins in a sample.  For 
quantifying proteins in a sample the technique is limited due to the use of 
denaturing gel electrophoresis.  The gel slices are cut manually which 
introduces variability between samples.  This variability is increased by 
differences in peptide recovery between samples.  The separation of proteins 
by gel electrophoresis prior to tryptic digestion can be avoided and an in-
solution digestion performed, but this increases the complexity of the sample 
and a smaller number of proteins will be identified.  To keep the complexity 
of the sample as low as possible, quantitative mass spectrometry was 
performed on whole protein samples rather than tryptic digests.  With this 
approach identifying the ions detected is not directly possible but the 
quantitative data should be more complete.  To ensure that the mass 
accuracy was as precise as possible Fourier transform ion cyclotron 
resonance mass spectrometry (FT-ICR MS) was used.  In most other mass 
spectrometers, for example quadropole and time-of-flight mass 
spectrometers, ion detection and m/z determination are not fundamentally 
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linked causing inaccuracies.  A quadrupole filters ions in an electric field 
prior to detection and a time-of-flight mass spectrometer detects ions 
following selection by flight time.  In contrast FT-ICR MS detects ions by 
their resonance frequency which is directly linked to their m/z ratio [181, 
182].  This means that sub-parts per million accuracies are possible with FT-
ICR MS. 
 
Due to the potential biological importance of exosomes in the CNS our first 
objective was to expand on our initial characterisation of the CSF exosomes 
in chapter 5 by exploring their proteome using GeLC-MS/MS.  Prior to 
searching for biomarkers in the CSF exosomes we need to estimate the 
variability between individuals.  Our second objective was to use label-free 
quantitative mass spectrometry to assess the variability in the CSF exosomal 
proteome across people. 
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6.2. Methods 
The same set of CSF samples used in chapter five were used in this study.  
CSF was collected from five patients undergoing thoraco-abdominal aortic 
aneurysm repair with full ethical approval.  These patients routinely have a 
CSF drain inserted as a standard aspect of their clinical management [114]. 
Exosomes were isolated from the CSF by ultracentrifugation as described in 
chapter 2.2.  
 
GeLC-MS/MS investigation was performed on the exosomes as described in 
chapter 2.9.1.  The proteome was fractionated into 10 fractions by gel 
electrophoresis prior to in-gel tryptic digestion and LC-MS/MS.  The list of 
identified proteins from each slice was then pooled and duplicates removed. 
 
The immunoglobulin depletion using protein G immobilized on agarose 
beads and subsequent western blot were performed as described in chapter 
2.8.1.   
 
Quantitative LC-FTICR MS (Chapter 2.9.3.) on whole proteins and LC-
MS/MS (Chapter 2.9.2.) following in-solution tryptic digestion (Chapter 
2.7.2.) was performed on the immunoglobulin depleted exosomal samples.  
The LC-MS/MS data was processed using the DataAnalysis (Bruker 
Daltonics, Billerica, MA, USA) software package version 4 SP4.  The 
MASCOT server version 2.2 from Matrix Science[128] was used to identify 
proteins from the MS/MS data.  Mascot searches were performed on the 
Swissprot 2010 database (519348 sequences) restricted to Homo sapiens (20287 
sequences) with the following parameters: a specified trypsin cleavage with a 
maximum of 2 possible missed cleavages, precursor and fragment ion 
  140 
tolerances of ±1.2 Da and ±0.6 Da respectively, fixed modification caused by 
carbamidomethylation on cysteines and variable modification by  oxidation 
on methionine.  Individual ion spectra were accepted at scores equivalent to 
p < 0.05.   
 
Further removal of the high abundance proteins was attempted using the 
Agilent Hu-PL7 multiple affinity removal system (MARS) column following 
the manufacturer’s instructions (Chapter 2.8.2.).  To verify that the MARS 
column was functioning correctly a plasma sample was obtained from a 
healthy 26 year old male. The plasma was prepared for the column following 
the manufacturer’s instructions.  Preparation of the exosomal samples was 
also based on the manufacturer’s instructions with some modifications as 
described in chapter 2.8.2.  Protein recovery from the column was assessed 
using SDS-PAGE as described in chapter 2.3.1. using the invitrogen gel 
system.  As a refinement of the in-solution digest method we used an on-
filter digestion protocol which was based on previous reports [183] with 
some minor modifications as described in chapter 2.7.3. 
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6.3. Results 
6.3.1. GeLC-MS/MS 
The CSF exosomal proteome was first investigated using GeLC-MS/MS. The 
list of identified proteins consisted predominantly of immunoglobulins.  
Only three other proteins were identified; alpha-2-macroglobulin, filamin A 
and galectin 3.  Querying these three proteins in the Online Mendelian 
Inheritance in Man (OMIM) database returned entries for the first two 
proteins linking them to neurological disease.  Alpha-2-macroglobulin is 
involved in Alzheimer’s disease where it mediates clearance of amyloid beta 
[184].  Filamin A is involved in cytoskeletal remodelling and is linked to X-
linked periventricular heterotopia in which neurons fail to migrate to the 
cerebral cortex [185].  Although not linked to a neurological disease in OMIM 
galectin 3 is a macrophage marker known to be expressed on microglial cells 
following activation, for example by ischemia [186, 187].  Our patient 
samples were obtained from a CSF drain during thoraco-abdominal aortic 
aneurysm repair surgery.  CSF drainage is one strategy used during this type 
of surgery to reduce ischemia which can lead to paraplegia [114] and it is 
possible that the presence of galectin 3 may reflect low-level ischemia. 
 
6.3.2. Immunoglobulin depletion by protein G  
High abundance immunoglobulins limited our ability to identify low 
abundance proteins. Therefore the exosome containing samples were 
incubated with protein G immobilized on agarose beads to reduce the 
amount of immunoglobulin.  Western blot for human immunoglobulins 
identified immunoglobulins ranging from below 36 kDa to above 148 kDa.  
Strong bands were present in the range 60-100 kDa.  After incubation with 
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protein G immobilized on agarose beads immunoglobulin bands were still 
present in the 60-100 kDa range but were reduced out with this mass range 
(Figure 6.1).  Exosomes, as measured by the presence of flotillin 1, remained 






























Figure 6.1  Western blot for human immunoglobulin  
The supernatant following high speed centrifugation, the purified exosomes 
and the purified exosomes following depletion of immunoglobulins by 
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Following immunoglobulin depletion each sample was split into two 
aliquots.  One aliquot was analysed directly by LC-FTICR MS.  In-solution 
digestion was performed on the second aliquot and the resulting peptides 




In-solution tryptic digestion followed by LC-MS/MS on each sample 
identified 19 proteins after the removal of duplicates and immunoglobulins 
(Table 6.1 and Appendix 2).  Checking each protein on the exocarta website 
[122] revealed that ten of the identified proteins had previously been found 
in exosomes or were closely related to proteins which had previously been 
found in exosomes.  Four proteins were cytosolic, three were nuclear, four 
were extracellular, four were membrane associated and the remainder were 
associated with different organelles of the cell.  Although not specific several 
identified proteins are enriched in the CNS.  Aquaporin 1 [188],  C-reactive 
protein, lysine-specific demethylase 6A, phosphoglycerate kinase 2 and 
sodium/iodide cotransporter have all been shown to be elevated in tissues of 
the CNS during transcriptional studies [189] and serine palmitoyltransferase 
3 is involved in the synthesis of sphingolipids which are required for signal 
transduction[190]   
 
   
Accessio
n Name Mascot score 
Sequence 
coverage 
(%) Peptides matched Protein Mass (kDa) 
Previously 
identified in 
exosomes Cellular location 
 P01023 Alpha-2-macroglobulin  1630 49 66 163 Yes [132, 138] Cytosol 
 Q08380 Galectin-3-binding protein  471 33 20 65  Extracellular 
 P20742 Pregnancy zone protein  202 6 10 164 Yes [34] Extracellular 
 P29972 Aquaporin-1  85 7 1 29 Yes [10, 131]  Plasma membrane 
 P48740 
Mannan-binding lectin serine 
protease 1  71 5 2 79 Yes [138] Extracellular 
 P29590 
Probable transcription factor 
PML  51 3 2 97  Cytosol 
 Q6P995  Protein FAM171B  43 0 3 92  Membrane 
 Q96RE9 Zinc finger protein 300  43 3 2 69 Related [131, 139] Nucleus 
 P00480 
Ornithine carbamoyltransferase, 
mitochondrial  43 2 1 40  Mitochondria 
 Q86T29 Zinc finger protein 605  43 1 1 74 Related [131, 139] Nucleus 
 Q9P2M7 Cingulin  43 0 1 136  Membrane 
 Q9NUV7 Serine palmitoyltransferase 3  40 5 2 62  
Endoplasmic 
reticulum 
 Q68D51 DENN domain-containing 40 0 1 106   
   
protein 2C  
 P02741 C-reactive protein  39 4 1 25  Extracellular 
 O15550 Lysine-specific demethylase 6A  38 1 2 154  Nucleus 
 Q8TF72 Shroom 3  38 0 1 217 Related [131]  Cytoskeleton 
 P36871 Phosphoglucomutase-1  37 2 2 61 Yes [131] Cytosol 
 P07205 Phosphoglycerate kinase 2  37 2 1 45 Yes [191]   Cytosol 
 Q92911  Sodium/iodide cotransporter  37 2 1 69 Yes [134]  Plasma membrane 
 
Table 6.1  Proteins identified in tryptic peptide LC-MS/MS data following depletion of immunoglobulins with protein 
G conjugated to agarose beads.
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6.3.4. LC-FTICR MS 
187 distinct proteins were identified in the five samples with 66 present in all 
five samples (Figure 6.2 and Appendix 3).  The coefficient of variation for all 
proteins present in two or more samples was calculated.  The median 
coefficient of variation was 81% and the 25th percentile was 68% (Figure 6.3).  
Within the 10 most abundant proteins the maximum coefficient of variation 
was 14% (Table 6.2). 
 
Variability in retention time complicates the comparison of proteins between 
samples and is one of the obstacles in label-free quantitative analyses.  
Manual and, in the latest software packages, automated alignment is 
necessary for comparison.  Particularly amongst the most abundant proteins 
there was little variability in the retention times which could be adjusted for 
by the automated alignment (Table 6.2). 
 
The molecular weight of the proteins detected by LC-FT ICR MS are lower 
than those identified by LC-MS/MS on the tryptic peptides (Figure 6.4).  This 
suggests that each technique provides additional information not available 















Figure 6.2  Ions detected following LC-FTICR MS on intact proteins from 
the CSF exosomes after immunoglobulin depletion with protein G 
conjugated to agarose beads.   
A)  The number of ions detected in each sample.  B)  The number of ions 
detected in different numbers of samples. 
 
 
Figure 6.3 Histogram of the coefficient of variation on LC-FT ICR MS 
protein abundance.










Retention Time (min) 
Retention 1 Retention 2 Retention 3 Retention 4 Retention 5 
659.5042 2 84905.83 9.48 32.35 32.34 32.44 32.41 32.39 
637.4901 2 79016.43 8.88 32.35 32.34 32.44 32.41 32.39 
681.5181 2 73538.83 10.40 32.35 32.34 32.44 32.41 32.39 
615.4762 2 71518.13 7.83 32.28 32.28 32.38 32.35 32.33 
703.5339 2 70627.72 10.75 32.42 32.40 32.51 32.47 32.44 
593.462 2 64351.47 9.18 32.28 32.28 32.38 32.35 32.33 
571.4479 2 51233.77 10.47 32.22 32.21 32.31 32.29 32.28 
725.5471 2 45044.52 9.20 32.42 32.40 32.51 32.47 32.44 
549.4341 2 41728.51 8.51 32.22 32.21 32.31 32.29 32.28 
527.42 2 29260.44 13.92 32.15 32.15 32.24 32.23 32.22 
Table 6.2 The ten most abundant proteins detected by LC-FT-ICR MS.








Figure 6.4  Comparison of the molecular weights of the proteins identified 
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6.3.5. Immunoglobulin depletion by MARS column liquid 
chromatography 
As an alternative to protein G immobilized agarose beads for 
immunoglobulin removal we used the Agilent HuPL-7 MARS column which 
is designed to remove the 7 most abundant proteins from human plasma and 
other biofluids.  In early tests we found that our sample was so dilute that we 
could not adequately recover sufficient protein from the column eluate to 
analyse on the mass spectrometer (Figure 6.5).  To verify that the column was 
performing correctly we ran the exosomal samples in conjunction with a 
plasma sample.  The UV spectra obtained from running a neat sample of 
plasma matched the sample spectra given by the manufacturer indicating that 
the column was functioning correctly and the issue was due to the low 
concentration (Figure 6.6A).  To investigate further the plasma sample was 
diluted so that the UV peak height matched the peak height for the CSF 
exosomal sample (Figure 6.6B).  The low abundance protein fraction from 
each sample was then digested using on-filter digestion and the resulting 
peptides analysed on the LC-MS/MS instrument.  In the plasma sample 48 
proteins were identified but again no proteins could be identified in the 
exosomal sample. 
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Figure 6.5  SDS-PAGE comparing protein present before and after 
separation on a MARS column. 
Samples are the exosomal preparation, following protein extraction with a 
methanol/chloroform (M/C) precipitation, following buffer exchange on a 
molecular weight cut-off filter and then the MARS column eluates for the low 

















Figure 6.6  UV absorbance on the MARS column eluate.   
A) Comparison of a CSF sample and a plasma sample loaded at the 
concentration recommended by the manufacturer.  B) Comparison of a CSF 
sample, a plasma sample diluted to approximately match the CSF sample and 
a blank sample. 
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6.4. Discussion 
 
Using GeLC-MS/MS and LC-MS/MS we have begun cataloguing the 
proteome of the CSF exosomes identifying 21 distinct proteins in total.  We 
have also used LC-FTICR MS to begin quantifying the components of the CSF 
exosomal proteome.  Comparison of the ions detected and their relative 
abundance indicates considerable consistency between samples. 
 
GeLC-MS/MS on a sample of CSF exosomes returned information on a 
smaller number of proteins than had been expected from previous experience 
with this technique in the urine.  The presence of high abundance proteins can 
mask low abundance proteins and, based on the number of immunoglobulins 
identified, we concluded this was why so few other proteins were identified.  
Although the urine also contains a highly abundant protein in uromodulin it 
is restricted to a narrow mass range.  The immunoglobulins in the CSF are 
present at molecular weights less than 36 kDa to more than 148 kDa as 
determined by western blot.  A polyclonal antibody raised against affinity 
purified IgG and known to react with IgG, IgA and IgM was used for this 
western blot.  With immunoglobulins present in each slice of the gel they 
effectively mask the lower abundance proteins.   
 
Our first attempt at resolving this issue was to incubate the exosomes with 
protein G immobilized on agarose beads.  Protein G binds to 
immunoglobulins in the sample and can be removed from the sample by 
centrifugation.  The exosomes, which have a lower sedimentation coefficient 
than the beads, remain in the supernatant.  This technique did not achieve 
complete removal of the immunoglobulins but did reduce the mass range 
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over which immunoglobulins were present.  Using this approach quantitative 
mass spectrometry was performed on whole proteins and on tryptic peptides.   
 
Quantitative LC-FTICR MS indicated substantial similarity between the five 
samples studied.  More than a third of the identified ions were present in all 
five samples.  The ion abundance was also similar between samples with a 
median coefficient of variation of 81%.  This analysis was on five biological 
replicates without technical replicates.  As such, it is not possible to separate 
out the biological and technical variation from the total variation.  The 
variation observed appears to be approximately comparable to similar 
previously published studies including one in the whole CSF [108].  
Biomarkers are often identified with fold changes sufficiently large to be 
detected against the background variation in this study.  For example 
Paweletz et al identified several ions that changed by more than eight fold 
with drug treatment [108] and Goonetilleke et al identified 34 protein spots 
altered in pneumococcal meningitis including serotransferrin which was 5.5 
fold down regulated in non-survivors [109].  The molecular weights of 
proteins detected by LC-FT ICR MS and identified by LC-MS/MS on tryptic 
peptides did not overlap.  The proteins detected by LC-FT ICR MS were 
smaller than those identified by LC-MS/MS.  This suggests that these two 
approaches are complimentary. 
 
Analysis of the tandem mass spectra data on the tryptic peptides identified 18 
additional proteins not identified in the GeLC-MS/MS analysis.  Although 
more proteins were identified than in the GeLC-MS/MS experiment the total 
number was still small in comparison to the urinary proteomics in chapter 
three and what might be expected from comparison with other exosomal 
studies.  This may in part be due to the use of in-solution digestion rather 
than in-gel digestion.  Following immunoglobulin depletion with the protein 
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G conjugated agarose beads the immunoglobulins, although still present, 
were restricted to a narrower range of masses.  This suggested that GeLC-
MS/MS would limit the immunoglobulins to a small number of the gel slices 
and the remaining slices would be sufficiently immunoglobulin depleted for 
the low abundance proteins to be detected.  GeLC-MS/MS was not used 
because it does not work well with quantitative mass spectrometry due to the 
increased variability introduced due to variable partitioning of proteins into 
the gel slices, different cut-offs used for the slices, and different recoveries 
from the slices.  In-solution digestion does not have these problems but all the 
proteins in the sample are mixed together meaning that the immunoglobulins 
still present overwhelm the low abundance proteins for the entire sample.  
Alternative separation techniques, such as strong cation exchange and reverse 
phase liquid chromatography, which are more reproducible than SDS-PAGE 
may be able to reduce the impact of the immunoglobulins without 
compromising the quantitative analysis.   
 
With immunoglobulins still detected by LC-MS/MS after incubating exosomes 
with protein G conjugated agarose beads we used the Agilent MARS Hu-PL7 
column as an alternative to remove the immunoglobulins.  This column 
performed well in a recent comparison [192].  It also functioned well in our 
hands when used on a plasma sample but unfortunately much of the protein 
in the CSF exosomal samples was lost during processing.  It is unclear 
whether the sample is lost on the MARS column itself or during the 
concentrating step on the molecular weight cut-off filter after the MARS 
column.  Performing the digestion on the filter did not improve recovery.  
Due to the insufficient removal of immunoglobulins with the protein G 
conjugated agarose beads and the poor recovery with the MARS column we 
are forced to conclude that obtaining a sufficient quantity of exosomal 
proteins with sufficient purity will require considerably larger volumes of 
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CSF.  Unfortunately the volumes used are already larger than we could 
reasonably expect to obtain during a biomarker discovery study.   
 
If the CSF exosomes are to be studied as a source of biomarkers then 
alternative approaches will be needed.  It is possible that alternative 
centrifugation methods such as isopycnic centrifugation or centrifugation on a 
sucrose cushion [116] may isolate a sufficiently pure sample with small 
enough losses to render the affinity purification techniques unnecessary.  
Alternatively the type of study could be changed from discovery proteomics 
to hypothesis driven proteomics for which a variety of more sensitive mass 
spectrometry techniques such as multiple reaction monitoring [193, 194] and 
antibody based techniques such as western blot and ELISA are available.  
There has also been growing interest in the presence of RNA in exosomes 
[195, 196].  The proteins present will not interfere with the detection of RNA 
and the use of RNA biomarkers is therefore another potential alternative. 
 
In summary, we have begun to catalogue the CSF exosomal proteome and 
quantify the variation between individuals.  We have used LC-MS/MS and 
LC-FT ICR MS which are complimentary approaches in this setting.  
Improvements in instrument sensitivity and/or sample preparation will be 
needed before expansion of this study.
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Robust biomarkers are powerful tools in the detection, diagnosis, monitoring 
and treatment of disease [197, 198].  We have focused on disease of the 
kidneys and central nervous system (CNS) as two areas where the need for 
biomarker development is particularly great.  Proteomic analysis of the urine 
and cerebrospinal fluid (CSF) should provide valuable insights into the state 
of the kidneys and CNS, respectively.  Proteomic analysis of any biofluid is 
complicated by the high complexity and dynamic range of the constituent 
proteins [100].  A variety of separation techniques have been developed to 
facilitate the proteomic analysis of biological samples.  Classical techniques 
separate proteins or peptides along a continuous gradient based on a 
physical property, for example hydrophobicity in reverse phase liquid 
chromatography, with the eluate being fed directly to the mass spectrometer 
or pooled into buckets for further processing.  For example two dimensional, 
and higher, liquid chromatography is gaining increasing use [199-202].  An 
alternative is to separate a discrete subproteome, for example the 
phosphoproteome [203, 204] or the glycoproteome [205] which is being 
studied in cancer proteomics particularly [206].  We have studied exosomes 
as an alternative subproteome. 
 
The first objective of this thesis was to establish an approach for the 
purification of exosomes from human urine.  Human samples are essential 
for biomarker validation but for understanding the role of exosomes the 
complex background inherent in human samples presents a significant 
challenge.  As an alternative, the second objective was to establish an in vitro 
model of exosome release and function in the kidneys. 
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Exosomes have previously been identified in the urine but so far no study 
has identified exosomes in the CSF.  Our third objective was to investigate 
the presence of exosomes in the CSF.  Our final objective, should exosomes 
be present in the CSF, was to investigate their proteome. 
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7.1. Purification strategy 
There is considerable variability in the purification strategies used in 
different studies.  Ultracentrifuges have different characteristics.  Speed and 
centrifugation duration can be adjusted to maintain conditions between 
instruments but this does not seem to be done in many published articles.  
Exosome purification protocols have been published [46, 116] but they focus 
on listing working combinations rather than documenting an optimal 
protocol with instructions on how to adapt the protocol to different 
ultracentrifuges.  The purification protocol and the ultracentrifugation 
conditions we employed were based on a conservative comparison with 
previously published protocols but validation of the protocol was still 
needed.  Using exosomal protein markers, density measurement and direct 
visualisation we have verified that our protocol does purify exosomes from 
human urine. 
 
Comparison of exosome characteristics from different biofluids or cell types 
is potentially complicated by the variation in purification protocol.  For 
example, the reported size distribution of exosomes varies between reports 
potentially due to differences in the centrifugation protocol used.  
Normalising protocols by k-factor and centrifugation time should minimise 
protocol variability.  Ultrafiltration is another potential approach for 
exosome purification [47, 207, 208].  This approach is a recent development.  
If exosome preparations obtained by ultrafiltration and ultracentrifugation 
are comparable [47] standardising on a ultrafiltration protocol may be less 
problematic as centrifuge type and speed should have less impact on the 
purified sample.  Such standardisation should facilitate protocol migration to 
the clinic where access to an ultracentrifuge is unlikely. 
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7.2. In vitro model 
The urine contains exosomes released from the entire length of the nephron 
[207].  Fluorescence activated cell sorting on exosomes is not possible due to 
their small size [209] and although partial separation of exosomes from a 
specific section of the nephron may be possible using immuno-precipitation 
the resulting sample would be impure and unlikely to contain only the 
exosomes released by the nephron section of interest.  An in vitro model 
avoids the need to isolate a sub-population of the exosomes and facilitates 
pharmacological modulation.  Using a murine cortical collecting duct cell 
line an in vitro model for the study of exosomes in the kidney has been 
established. 
 
Exosome release was rapidly increased following stimulation with 
ionomycin.  Exosome release following ionomycin stimulation is cell type 
specific.  In the haematopoietic cell line K562 ionomycin increases exosome 
release [210].  In human podocytes, in contrast to the mCCD cells, no change 
was observed [40].  This suggests that even within the same organ different 
mechanisms of release are important.  No change in exosome release, as 
quantified by marker protein, was observed with dDAVP or cisplatin 
treatment.  AQP2 did increase in the exosomes released following dDAVP 
stimulation and this matched an increase in the cells.  This process took 96 
hours which was consistent with previous observations in this cell line [161]. 
 
Applying exosomes from dDAVP treated cells back on to mCCD cells caused 
an increase in AQP2 in the cell lysates.  Previous studies investigating the 
interactions between cells and exosomes have found exosomes to both 
adhere to the surface of cells and to enter cells [195, 211].  The protocol used 
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in this study is not able to differentiate between AQP2 which has entered the 
cell and AQP2 which is present in exosomes adhering to the cell surface.  
Although the wash step prior to collecting the cell lysates could potentially 
be made more stringent removing more of the adherent exosomes there is no 
way to be sure that all exosomes on the cell surface have been removed.  In 
previous studies direct visualisation using fluorescence [212] and electron 
[213, 214] microscopy has been used to identify exosomes both on the cell 
surface and entering the cell.  Combining labelling and direct visualisation 
can also be used to identify the source and destination of proteins in 
exosomes.  Biotinylation of cell surface proteins can be used to track 
incorporation into exosomes [215] or measure changes at the plasma 
membrane following incubation with exosomes [212].  Incorporation of 
proteins into the plasma membrane can also be tracked by labelling the 
exosomes [213].  Such techniques powerfully demonstrate entry of exosomes 
into the cells but quantifying this process is challenging.  Sub-cellular 
fractionation of the cells and subsequent western blot should enable 
quantification of the AQP2 in the different regions of the cell. 
 
The effect of the exogenously applied exosomes on these cells requires 
further study.  Exosomes have previously been described as conveyors of 
biological activity and information [1, 16, 42, 173, 216-218] and we are 
beginning to understand the mechanisms of this transfer.  Exosomes share 
the cell surface markers of their cell of origin and can potentially propagate 
the same signals.  Exosome mediated signalling events are well characterised 
in the immune system.  Depending on their cell of origin exosomes can 
present major histocompatibility complex (MHC) class I [219], class II [12] 
and TCR/CD3 complexes [162].  Exosomes can also transfer protein [208, 212, 
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220] and RNA [195, 221] following cell entry.  Valadi et al applied exosomes 
from a mouse cell line on to a human cell line to differentiate transferred 
proteins from host proteins [195].  Using proteomic analysis proteins 
originating from the mouse were identified in the cells.  These proteins were 
not identified in the exosomes indicating de novo synthesis from exosomal 
RNA.  If the exosomes entered the mCCD cells the increase in AQP2 could 
potentially be AQP2 protein which was present in the exosomes or de novo 
synthesis of AQP2 from mRNA transcripts carried in the exosomes.  
Identifying whether transfer of RNA or protein is responsible for the 
presence of AQP2 will require a method of separating the two sources or 
blocking one of them.  Labelling the exosomes prior to applying them to the 
cells should differentiate protein transferred in the exosomes from newly 
translated protein.  Alternatively blocking translation would allow the 
protein transferred to be measured.  With a 48 hour incubation translation 
blockade would have side effects on the cells.  Several other studies have 
used shorter incubation times during which blockade of translation should 
not negatively effect the cells. 
  165 
7.3. Exosomes in CSF 
We hypothesized that exosomes would be present in human CSF and would 
be a source of biomarkers for the CNS.  Adapting the urinary protocol for the 
CSF exosomes were identified using western blot for exosomal markers, 
isopycnic centrifugation and transmission electron microscopy.  The 
potential role of exosomes in the CNS has been discussed previously [222, 
223] with their role in communication and signalling highlighted.  There is 
insufficient information available to more than theorise on their activity in 
healthy tissue [191] but there is evidence of a role in a number of diseases [32, 
34, 35, 170-172]. 
 
Understanding their proteome will be important in identifying their role in 
both healthy tissue and disease.  Using GeLC-MS/MS and LC-MS/MS we 
identified 21 proteins.  This is a relatively small number of proteins which we 
attributed to the high abundance of immunoglobulins in the exosomal 
samples.  Attempts to remove the high abundance immunoglobulins were 
only partially successful with all the protein in the exosomal sample 
eventually lost.  With any purification there is a trade off to be made between 
purity and recovery.  Our attempts to achieve sufficient purity resulted in 
insufficient recovery for analysis by LC-MS/MS.  We were fortunate to have 
access to large volumes of CSF but the volume of CSF routinely obtainable 
will be limited so increasing the amount of starting material will not be 
feasible.  If biomarker discovery using the CSF exosomes is to be viable, it 
will be necessary to either improve the recovery rate or increase the 
sensitivity and/or specificity of the analysis.  At the moment there is no 
obvious approach to increasing recovery while achieving sufficient purity.  
Ultrafiltration has been suggested as an alternative to ultracentrifugation but 
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there is currently no evidence indicating recovery or purity will be improved 
[47].  Western blot, together with other antibody based technologies, is both 
more sensitive and specific but is limited in the number of proteins it is 
possible to investigate.  More recently several studies have identified RNA as 
present in exosomes [195, 224].  A potential mechanism for the inclusion of 
miRNA in exosomes has been suggested [225, 226] with increasing focus on 
exosomal miRNA as a source of potential biomarkers [196, 221, 227, 228].  
The detection method for RNA, usually PCR or microarray, is insensitive to 
interference from high abundance proteins and so the need for highly 
purified exosomal samples is avoided.  Although the study design will need 
to be altered to avoid the issues with high abundance immunoglobulins the 
CSF exosomes are biologically important and warrant continued study. 
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7.4. Mass spectrometry 
Using GeLC-MS/MS we were able to identify 76 proteins in the urinary 
exosomes.  The urinary exosomes have been well studied [10, 131] with 1132 
proteins identified in the latest study [131].  The overlap of our dataset for 
the urinary exosomal proteome with previous reports was higher than for 
the CSF exosomal proteome.  This would be expected given that the CSF 
exosomes are novel.  The differences between our urinary exosomal 
proteome dataset and previous reports are still substantial; 23 out of the 76 
proteins identified had not been seen in previous reports.  This is certainly 
not unprecedented; a comparison of a literature review and three different 
proteomics experiments looking at the plasma proteome identified 1,175 
proteins of which only 195 (16%) were present in more than one result set 
[229].  The mass spectrometry techniques used are as yet not able to identify 
all proteins in a sample and on each repetition will randomly sample 
different ions leading to new proteins being identified and previously 
identified proteins being missed.  Differences in the databases and 
algorithms used can also lead to differences in the datasets generated [230].  
With a large fraction of identified proteins unique to individual datasets it is 
likely that a significant proportion of proteins are yet to be identified.  
Although the urinary exosomal proteome would be expected to be smaller 
that the plasma proteome at the moment it is dwarfed by the dataset on this 
more extensively studied proteome [231, 232]. 
 
Qualitative mass spectrometry data is valuable in understanding the 
composition of a sample but additional context can be gained by comparison 
against other samples.  A variety of approaches utilising different labels [73, 
76-78] have been developed to enable such comparisons but these 
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approaches have drawbacks [74, 75].  As an alternative we have explored the 
ability of label-free mass spectrometry [159] to generate quantitative data in 
our samples.  In contrast to label based techniques, label-free mass 
spectrometry requires no additional sample processing steps compared to a 
qualitative study.  Label-free mass spectrometry is becoming increasingly 
viable with improvements in inter-analysis variability and data analysis.  The 
tools necessary to perform the data analysis on these studies are improving 
rapidly [233].  The data analysis software package used in chapter 3 is a 
general purpose package and although capable of label-free analysis this was 
largely a manual process requiring the operator to select matching ions 
between samples and specify the peaks to be quantified.  By comparison the 
progenesis LC-MS software package used in chapter 6 is specifically 
designed for label-free quantitative mass spectrometry and is able to 
automate the alignment and quantitation tasks with the operator supervising 
and correcting the few erroneous matches.  Further work is needed to 
determine the experimental variability but the results seen with both the 
manual approach in chapter 3 and the automated approach used in chapter 6 
suggest that label-free quantitative mass spectrometry should be a valuable 
tool during biomarker discovery. 
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7.5 Future Work 
This work could be continued in a number of distinct, though mutually 
supportive, directions.  The purification strategy used was based on a 
conservative interpretation of the existing literature and subsequent 
validation in the urine.  This purification strategy was inadequate in the CSF 
with immunoglobulin contamination remaining problematic.  A comparison 
of different ultracentrifugation protocols together with alternatives such as 
ultrafiltration should be conducted looking at recovery of exosomes and the 
purity of the resulting sample.  Such a study may improve proteomic 
analysis of the CSF exosomes by increasing the signal (exosomes) and 
reducing the noise (non-exosomal proteins).  Future work should also 
investigate alternative solutes to sucrose for isopycnic centrifugation and 
subsequent density determination.  Sucrose gradients have been widely used 
but are time consuming to prepare in comparison to alternatives such as 
Percoll [207].  As particles will migrate to different densities based on the 
solute used comparison across studies will not be possible until exosomes 
have been analysed, side by side, on both gradients. 
 
In the present study AQP2 containing exosomes have been applied to the 
mCCD cells resulting in an increase in AQP2 in the cell lysate.  Whether the 
exosomes enter the cells or remain attached to the surface remains to be 
investigated.  In published studies, labelling the exosomes and fluorescence 
microscopy on the cells has been used to demonstrate exosome 
internalisation [211].  A similar approach could be used for the mCCD cells.  
Increased AQP2 within the cell may increase water flux across the cells.  
Water flux, for example as measured by gravimetry [234], is a functional 
assay amenable to future study. 
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The mCCD cell line is being used as a model of the collecting duct.  A 
proteomic comparison between urinary and mCCD cell derived exosomes 
would further validate this in vitro model.  In addition to CCD derived 
exosomes the cells of the collecting duct will also be exposed to exosomes 
shed from cells upstream in the nephron and, possibly, exosomes from 
infiltrating inflammatory cells.  Expanding this model to include other cell 






7.6. Concluding Remarks 
Exosomes have a variety of biological roles.  Our purification of exosomes in 
the urine and CSF provides a potentially important target for biomarker 
discovery and investigation of a novel mechanism of intercellular 
communication in the kidneys and CNS.  The development of the mCCD cell 
model will facilitate the study of the urinary exosomes.  Label-free 
quantitative mass spectrometry is still a novel technique but has promise for 
discovery stage proteomic studies. 
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Appendix 1 – GeLC-MS/MS protein identification of 
urinary exosomal proteins 
 
Additional information on any protein identifications made by one ion in 
any single band is presented.  The m/z ratio, charge and sequence of the 
peptide are included.  The presence of any peptides linked to the identified 











multiple bands m/z Charge Peptide 
Carbonic anhydrase II  NP_000058 1 93 Only one ion detected 
in a single band 




epsilon polypeptide  
NP_006752 1 93 Two ions detected in 
the combined analysis 
1044.535 2 K.AAFDDAIAELDTLSEESYK.D 
973.062 2 K.LAEQAERYDEMVESMK.K 
Calbindin D28K  AAB19408 1 76 Only one ion detected 
in a single band 
792.243 2 K.ELQNLIQELQQAR.K 
Alpha globin  CAA23749 1 55 Only one ion detected 
in a single band 
765.142 2 K.VGAHAGEYGAEALER.H 
Phosphoglycerate 
kinase 2 
CAA28872 1 49 Two ions detected in 
the combined analysis 
818.068 2 K.LGDVYVNDAFGTAHR.A 
467.801 2 K.ALMDEIVK.A 
Gamma-
glutamyltransferase 1 
AAA52546 1 122 Four ions detected in 
combined analysis 
701.706 2 R.NIDQAVTAALETR.H 
938.974 2 R.TVIEQQPVLCEVFCR.D 
577.434 2 K.GGLSVAVPGEIR.G 
887.653 1 K.GLAAALENK.R 
Bile salt export pump  AAD28285 1 120 Three ions detected in 
combined analysis 
924.53 2 K.ILLLDEATSALDTESEK.T 
672.219 2 K.EIPMERVIAAAK.Q 





AAF67321 1 66 Ion detected in two 
bands 
717.736 2 R.ETAFEEDVQLPR.A 
Napsin A 
preproprotein  
NP_004842 1 80 Only one ion detected 
in a single band 
1088.087 2 K.GCAAILDTGTSLITGPTEEIR.A 
Aquaporin 1 AAC16481 1 77 Only one ion detected 
in a single band 
824.119 2 K.YPVGNNQTAVQDNVK.V 
Desmoglein-1 
precursor  
Q02413 1 76 Two ions detected in 
the combined analysis 
818.729 2 K.YQGTILSIDDNLQR.T 
754.931 3 K.VVKPLDYEAMQSLQLSIGVR.N 
CD26 CAA43118 1 48 Three ions detected in 
combined analysis 
789.739 2 R.LGTFEVEDQIEAAR.Q 
749.072 2 K.LAYVWNNDIYVK.I 
969.171 2 K.FWYQMILPPHFDKSK.K 
Tetraspan TM4SF 
(Tspan-1)  
AAC69714 1 45 Only one ion detected 
in a single band 
814.332 2 K.VEGCFNQLLYDIR.T 
Apolipoprotein J 
precursor 
AAA51765 1 60 Only one ion detected 
in a single band 
645.113 2 R.ELDESLQVAER.L 
CD59 antigen p18-20  NP_000602 1 50 Only one ion detected 
in a single band 
770.572 2 K.FEHCNFNDVTTR.L 
Lysosomal pepstatin 
insensitive protease  
AAB80725 1 101 Two ions detected in 
combined analysis 
992.156 2 R.AYPDVAALSDGYWVVSNR.V 
803.147 2 R.LYQQHGAGLFDVTR.G 
  
Beta-trace 23.5 kda 
glycoprotein  
AAB24507 1 46 Only one ion detected 
in a single band 
893.115 2 -.APEAQVSVQPNFQQDK.F 
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Appendix 2 – LC-MS/MS protein identification of CSF 
exosomal proteins 
Additional information on any protein identifications made by one ion is 
presented.  The m/z ratio, charge and sequence of the peptide are included.  
For each peptide the fragmentation spectra is shown and the peaks used to 
identify the peptide indicated. 
 
   
 
Accession Name Mascot score Seq coverage (%) m/z z Peptide 
 P29972 Aquaporin-1  85 7 1156.5566 2 VWTSGQVEEYDLDADDINSR 
 P00480 Ornithine carbamoyltransferase, mitochondrial  43 2 495.7828 2 QSDLDTLAK 
 Q9P2M7 Cingulin  43 0 379.3114 2 IEVLQR 
 Q68D51 DENN domain-containing protein 2C  40 0 359.2776 2 NSQTIR 
 P02741 C-reactive protein  39 4 564.8655 2 ESDTSYVSLK 
 Q8TF72 Shroom 3  38 0 466.7784 2 SSPATADKR 
 P07205 Phosphoglycerate kinase 2  37 2 503.7981 2 DCVGAEVEK 
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1 1407.642 704.3250 1390.616 695.8117 1389.632 695.3197 L 1018.480 509.7436 1001.453 501.2304 1000.469 500.7383 9 
   





















































































S 262.1510 131.5791 245.1244 123.0659 244.1404 122.5738 2 
2
0 






























1 129.0659 65.0366 112.0393 56.5233     Q             9 
2 216.0979 108.5526 199.0713 100.0393 198.0873 99.5473 S 862.4516 431.7295 845.4251 423.2162 844.4411 422.7242 8 
3 331.1248 166.0661 314.0983 157.5528 313.1143 157.0608 D 775.4196 388.2134 758.3931 379.7002 757.4090 379.2082 7 
4 444.2089 222.6081 427.1823 214.0948 426.1983 213.6028 L 660.3927 330.7000 643.3661 322.1867 642.3821 321.6947 6 
5 559.2358 280.1216 542.2093 271.6083 541.2253 271.1163 D 547.3086 274.1579 530.2821 265.6447 529.2980 265.1527 5 
6 660.2835 330.6454 643.2570 322.1321 642.2729 321.6401 T 432.2817 216.6445 415.2551 208.1312 414.2711 207.6392 4 
7 773.3676 387.1874 756.3410 378.6742 755.3570 378.1821 L 331.2340 166.1206 314.2074 157.6074     3 
8 844.4047 422.7060 827.3781 414.1927 826.3941 413.7007 A 218.1499 109.5786 201.1234 101.0653     2 
































1 114.0913 57.5493         I             6 
2 243.1339 122.0706     225.1234 113.0653 E 644.3726 322.6899 627.3461 314.1767 626.3620 313.6847 5 
3 342.2023 171.6048     324.1918 162.5995 V 515.3300 258.1686 498.3035 249.6554     4 
4 455.2864 228.1468     437.2758 219.1416 L 416.2616 208.6344 399.2350 200.1212     3 
5 583.3450 292.1761 566.3184 283.6629 565.3344 283.1709 Q 303.1775 152.0924 286.1510 143.5791     2 

































1 115.0502 58.0287 98.0237 49.5155     N             6 
2 202.0822 101.5448 185.0557 93.0315 184.0717 92.5395 S 604.3413 302.6743 587.3148 294.1610 586.3307 293.6690 5 
3 330.1408 165.5740 313.1143 157.0608 312.1302 156.5688 Q 517.3093 259.1583 500.2827 250.6450 499.2987 250.1530 4 
4 431.1885 216.0979 414.1619 207.5846 413.1779 207.0926 T 389.2507 195.1290 372.2241 186.6157 371.2401 186.1237 3 
5 544.2726 272.6399 527.2460 264.1266 526.2620 263.6346 I 288.2030 144.6051 271.1765 136.0919     2 































1 130.0499 65.5286 112.0393 56.5233 E             10 
2 217.0819 109.0446 199.0713 100.0393 S 999.4993 500.2533 982.4728 491.7400 981.4888 491.2480 9 
3 332.1088 166.5581 314.0983 157.5528 D 912.4673 456.7373 895.4407 448.2240 894.4567 447.7320 8 
4 433.1565 217.0819 415.1460 208.0766 T 797.4403 399.2238 780.4138 390.7105 779.4298 390.2185 7 
5 520.1885 260.5979 502.1780 251.5926 S 696.3927 348.7000 679.3661 340.1867 678.3821 339.6947 6 
6 683.2519 342.1296 665.2413 333.1243 Y 609.3606 305.1840 592.3341 296.6707 591.3501 296.1787 5 
7 782.3203 391.6638 764.3097 382.6585 V 446.2973 223.6523 429.2708 215.1390 428.2867 214.6470 4 
8 869.3523 435.1798 851.3418 426.1745 S 347.2289 174.1181 330.2023 165.6048 329.2183 165.1128 3 
9 982.4364 491.7218 964.4258 482.7165 L 260.1969 130.6021 243.1703 122.0888     2 
































1 88.0393 44.5233     70.0287 35.5180 S             9 
2 175.0713 88.0393     157.0608 79.0340 S 845.4476 423.2274 828.4210 414.7141 827.4370 414.2221 8 
3 272.1241 136.5657     254.1135 127.5604 P 758.4155 379.7114 741.3890 371.1981 740.4050 370.7061 7 
4 343.1612 172.0842     325.1506 163.0790 A 661.3628 331.1850 644.3362 322.6717 643.3522 322.1797 6 
5 444.2089 222.6081     426.1983 213.6028 T 590.3257 295.6665 573.2991 287.1532 572.3151 286.6612 5 
6 515.2460 258.1266     497.2354 249.1214 A 489.2780 245.1426 472.2514 236.6293 471.2674 236.1373 4 
7 630.2729 315.6401     612.2624 306.6348 D 418.2409 209.6241 401.2143 201.1108 400.2303 200.6188 3 
8 758.3679 379.6876 741.3414 371.1743 740.3573 370.6823 K 303.2139 152.1106 286.1874 143.5973     2 






























1 116.0342 58.5207 98.0237 49.5155 D             9 
2 276.0649 138.5361 258.0543 129.5308 C 891.4241 446.2157 874.3975 437.7024 873.4135 437.2104 8 
3 375.1333 188.0703 357.1227 179.0650 V 731.3934 366.2003 714.3668 357.6871 713.3828 357.1951 7 
4 432.1548 216.5810 414.1442 207.5757 G 632.3250 316.6661 615.2984 308.1529 614.3144 307.6608 6 
5 503.1919 252.0996 485.1813 243.0943 A 575.3035 288.1554 558.2770 279.6421 557.2930 279.1501 5 
6 632.2345 316.6209 614.2239 307.6156 E 504.2664 252.6368 487.2399 244.1236 486.2558 243.6316 4 
7 731.3029 366.1551 713.2923 357.1498 V 375.2238 188.1155 358.1973 179.6023 357.2132 179.1103 3 
8 860.3455 430.6764 842.3349 421.6711 E 276.1554 138.5813 259.1288 130.0681 258.1448 129.5761 2 






























1 88.0393 44.5233 70.0287 35.5180 S             14 
2 189.0870 95.0471 171.0764 86.0418 T 1511.8369 756.4221 1494.8104 747.9088 1493.8263 747.4168 13 
3 302.1710 151.5892 284.1605 142.5839 L 1410.7892 705.8983 1393.7627 697.3850 1392.7787 696.8930 12 
4 373.2082 187.1077 355.1976 178.1024 A 1297.7052 649.3562 1280.6786 640.8429 1279.6946 640.3509 11 
5 470.2609 235.6341 452.2504 226.6288 P 1226.6681 613.8377 1209.6415 605.3244 1208.6575 604.8324 10 
6 527.2824 264.1448 509.2718 255.1396 G 1129.6153 565.3113 1112.5887 556.7980 1111.6047 556.3060 9 
7 640.3665 320.6869 622.3559 311.6816 L 1072.5938 536.8006 1055.5673 528.2873 1054.5833 527.7953 8 
8 753.4505 377.2289 735.4400 368.2236 L 959.5098 480.2585 942.4832 471.7452 941.4992 471.2532 7 
9 939.5298 470.2686 921.5193 461.2633 W 846.4257 423.7165 829.3991 415.2032 828.4151 414.7112 6 
10 1125.6091 563.3082 1107.5986 554.3029 W 660.3464 330.6768 643.3198 322.1636 642.3358 321.6715 5 
11 1240.6361 620.8217 1222.6255 611.8164 D 474.2671 237.6372 457.2405 229.1239 456.2565 228.6319 4 
12 1353.7202 677.3637 1335.7096 668.3584 L 359.2401 180.1237 342.2136 171.6104     3 
13 1424.7573 712.8823 1406.7467 703.8770 A 246.1561 123.5817 229.1295 115.0684     2 
14         R 175.1190 88.0631 158.0924 79.5498     1 
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Appendix 3 - Quantitative LC-FT-ICR MS on the CSF 
exosomal proteome 
M/z ratio and charge for each species detected together with the retention 










Normalized abundance Sample retention time (min) 
1 2 3 4 5 1 2 3 4 5 
659.5042 32.351 0.946 2 93615.42 72355.22 83941.47 89867.90 84749.16 32.351 32.340 32.443 32.406 32.387 
615.4762 32.283 1.213 2 71163.90 62386.37 74296.14 77277.90 72466.33 32.283 32.276 32.376 32.346 32.332 
637.4901 32.351 1.146 2 84422.49 66849.94 79960.09 82860.75 80988.87 32.351 32.340 32.443 32.406 32.387 
593.462 32.283 1.079 2 63779.87 54740.21 65497.96 70420.12 67319.20 32.283 32.276 32.376 32.346 32.332 
681.5181 32.351 0.879 2 78253.89 61886.29 74023.22 81999.56 71531.17 32.351 32.340 32.443 32.406 32.387 
571.4479 32.216 1.079 2 55120.43 42057.73 54722.79 53133.37 51134.51 32.216 32.212 32.309 32.286 32.278 
549.4341 32.216 1.146 2 40206.44 36343.37 42586.65 44967.21 44538.88 32.216 32.212 32.309 32.286 32.278 
703.5339 32.418 1.146 2 80279.36 60640.08 69169.68 75640.27 67409.19 32.418 32.404 32.511 32.467 32.441 
527.42 32.149 0.946 2 33720.64 23439.49 27400.31 32273.41 29468.34 32.149 32.148 32.241 32.225 32.223 
725.5471 32.418 0.744 2 46527.28 38802.53 43252.91 49502.39 47137.49 32.418 32.404 32.511 32.467 32.441 
505.4062 32.149 0.674 2 18031.63 15215.96 17339.12 18115.26 17887.61 32.149 32.148 32.241 32.225 32.223 
747.5613 32.418 0.475 2 21882.50 19172.58 22106.01 24988.33 21334.74 32.418 32.404 32.511 32.467 32.441 
579.4456 29.997 0.531 2 13792.26 11058.62 12324.22 10185.95 10885.83 29.997 30.056 30.095 30.061 30.059 
483.3922 32.081 0.538 2 8320.90 6827.74 7289.89 9466.19 7959.34 32.081 32.084 32.174 32.127 32.158 
557.4315 29.865 0.464 2 11195.72 7505.80 10420.83 10904.17 9422.82 29.865 29.934 29.960 29.931 29.928 
623.4737 30.132 0.540 2 14994.75 13420.90 12840.42 13244.72 14297.62 30.132 30.177 30.230 30.192 30.190 
601.4598 30.065 0.538 2 12383.94 12635.61 14659.69 13541.22 14250.50 30.065 30.116 30.162 30.127 30.124 
645.4879 30.197 0.338 2 14915.40 13813.61 16110.67 10648.83 12787.44 30.197 30.242 30.297 30.257 30.255 
535.4177 29.799 0.464 2 9350.02 7021.29 7744.54 7796.76 7653.47 29.799 29.865 29.893 29.865 29.863 
667.5018 30.264 0.405 2 16288.18 12110.31 13133.84 12879.31 11899.28 30.264 30.320 30.364 30.323 30.321 
332.802 33.228 0.134 2 6997.25 632.70 0.00 122.29 163.77 33.228 33.233 33.314 33.298 33.260 
325.7939 32.960 0.134 2 5999.44 267.49 138.03 129.53 0.00 32.960 32.960 33.046 33.018 32.976 
769.5756 32.418 0.338 2 8658.53 9534.59 9511.62 9570.94 11479.14 32.418 32.404 32.511 32.467 32.441 
319.316 33.896 0.267 2 773.24 1338.31 1601.25 1616.30 1435.13 33.896 33.912 33.986 33.958 33.926 
689.5156 30.333 0.340 2 12898.35 9541.09 10584.42 8554.79 9821.96 30.333 30.404 30.432 30.388 30.386 
513.4035 29.734 0.397 2 7962.66 5050.83 6607.53 5451.01 4834.30 29.734 29.793 29.827 29.800 29.798 
333.3321 34.299 0.336 2 864.18 1084.99 1461.25 1289.31 1354.98 34.299 34.320 34.388 34.353 34.321 
334.3217 33.830 0.270 2 704.70 969.44 1392.88 1056.89 1310.62 33.830 33.844 33.920 33.866 33.871 
  
546.392 24.406 0.606 2 6948.89 7368.71 5254.05 4818.06 4666.68 24.406 24.426 24.465 24.489 24.440 
502.3643 24.139 0.467 2 5280.04 5566.87 5977.22 5481.34 4659.59 24.139 24.153 24.199 24.229 24.211 
524.3781 24.272 0.467 2 5725.37 7694.27 6372.62 6105.15 6500.01 24.272 24.290 24.330 24.359 24.325 
491.3899 29.601 0.333 2 4420.51 2395.54 2664.66 2782.95 3149.76 29.601 29.653 29.694 29.669 29.667 
628.9766 32.351 0.337 2 3719.39 4906.42 3754.67 4081.11 3632.90 32.351 32.340 32.443 32.406 32.387 
562.9341 32.216 0.404 2 2798.26 3315.05 2844.20 3881.47 3141.42 32.216 32.212 32.309 32.286 32.278 
606.9628 32.283 0.337 2 2143.03 3898.61 3828.99 3976.05 2586.26 32.283 32.276 32.376 32.346 32.332 
650.9906 32.351 0.337 2 2367.25 3805.18 3380.55 2036.20 4303.49 32.351 32.340 32.443 32.406 32.387 
683.9962 32.351 0.202 2 1950.06 1992.84 2207.70 3286.25 2451.66 32.351 32.340 32.443 32.406 32.387 
568.4063 24.541 0.337 2 2893.92 5412.71 4761.11 3501.36 3923.36 24.541 24.562 24.600 24.644 24.596 
348.3378 34.165 0.269 2 433.72 866.71 817.72 870.57 842.59 34.165 34.183 34.255 34.233 34.189 
584.9484 32.283 0.337 2 4595.11 3045.70 4947.84 2785.94 3548.75 32.283 32.276 32.376 32.346 32.332 
802.3012 34.030 0.403 3 30840.18 14465.07 13798.31 12499.74 13415.32 34.030 34.049 34.121 34.114 34.057 
461.3787 32.081 0.336 2 1867.00 1298.47 2096.96 1808.73 2132.38 32.081 32.084 32.174 32.127 32.158 
617.9538 32.283 0.270 2 1941.06 1716.23 2161.54 3683.47 2703.12 32.283 32.276 32.376 32.346 32.332 
595.9394 32.283 0.202 2 1396.48 2045.06 1787.94 2349.88 1899.37 32.283 32.276 32.376 32.346 32.332 
791.589 32.485 0.271 2 6803.52 8065.43 6928.79 5537.54 3565.10 32.485 32.473 32.578 32.529 32.496 
711.53 30.403 0.273 2 5950.06 5350.98 6091.66 6889.48 4079.06 30.403 30.486 30.499 30.454 30.452 
673.0046 32.418 0.269 2 3366.25 3513.59 3584.72 5233.62 3564.09 32.418 32.404 32.511 32.467 32.441 
540.9207 32.216 0.269 2 1472.00 1437.71 1878.83 2083.41 1507.63 32.216 32.212 32.309 32.286 32.278 
573.9257 32.216 0.270 2 1641.89 1448.24 1082.31 1955.68 1360.43 32.216 32.212 32.309 32.286 32.278 
1222.552 17.498 0.269 8 0.00 43816.56 0.00 9284.97 3283.08 17.498 17.494 17.553 17.605 17.594 
1245.145 25.210 0.202 2 18303.47 8658.81 5893.86 4190.48 0.00 25.210 25.243 25.269 25.349 25.308 
661.4893 33.830 0.270 14 1045.59 3484.32 5481.59 3542.37 3073.13 33.830 33.844 33.920 33.866 33.871 
1452.524 25.277 0.136 8 3763.52 2564.84 11041.72 0.00 5634.12 25.277 25.310 25.337 25.414 25.376 
401.7857 33.497 0.333 2 198.89 1595.75 1009.97 1238.45 749.19 33.497 33.504 33.585 33.576 33.598 
698.582 34.030 0.269 13 2330.24 1049.39 1712.98 2067.70 1848.79 34.030 34.049 34.121 34.114 34.057 
1412.815 25.210 0.133 6 34473.26 16262.18 15176.44 19860.74 28210.71 25.210 25.243 25.269 25.349 25.308 
802.3015 20.518 0.269 5 14511.33 6689.27 9713.37 10324.14 9309.27 20.518 20.575 20.573 20.610 20.636 
469.3444 34.367 0.270 10 634.29 1889.90 2119.48 2086.46 2517.79 34.367 34.390 34.455 34.413 34.387 
518.9065 32.216 0.202 2 1503.29 1863.28 438.30 571.46 1006.21 32.216 32.212 32.309 32.286 32.278 
480.3503 23.872 0.332 2 2381.53 3139.38 2700.10 1982.86 2078.93 23.872 23.885 23.928 23.968 23.969 
  
586.4662 33.562 0.266 11 2970.62 2256.68 3415.49 2855.77 2924.99 33.562 33.571 33.650 33.636 33.653 
639.9685 32.351 0.270 2 2287.15 2376.46 1252.72 2886.08 2031.58 32.351 32.340 32.443 32.406 32.387 
590.42 24.743 0.269 2 1302.17 3498.68 1694.33 1598.08 2515.38 24.743 24.766 24.800 24.879 24.832 
813.6044 32.485 0.271 2 4298.73 3545.89 3613.33 2658.92 4071.78 32.485 32.473 32.578 32.529 32.496 
546.4544 32.553 0.205 18 801.63 1638.93 1649.51 656.59 359.09 32.553 32.542 32.645 32.596 32.551 
854.6181 34.501 0.271 14 5043.57 5264.73 1938.40 1864.14 5467.83 34.501 34.525 34.588 34.532 34.519 
1161.954 25.210 0.133 4 1059.33 1717.11 4293.10 2337.76 5447.02 25.210 25.243 25.269 25.349 25.308 
1064.984 16.896 0.135 5 0.00 2908.05 0.00 4528.85 1451.67 16.896 16.852 16.949 16.997 16.975 
706.0097 32.351 0.135 2 549.68 1354.64 1697.71 0.00 2234.10 32.351 32.340 32.443 32.406 32.387 
661.9831 32.351 0.135 2 3242.00 2468.48 1578.54 2703.89 3279.64 32.351 32.340 32.443 32.406 32.387 
1260.559 16.963 0.135 7 0.00 9434.96 0.00 0.00 0.00 16.963 16.925 17.017 17.064 17.044 
552.4133 32.216 0.202 11 0.00 505.95 315.96 0.00 557.69 32.216 32.212 32.309 32.286 32.278 
1276.89 25.145 0.133 3 1961.86 6460.42 3490.65 11026.89 6965.48 25.145 25.176 25.202 25.284 25.241 
1089.076 25.210 0.133 3 38.14 5415.59 4540.32 682.89 0.84 25.210 25.243 25.269 25.349 25.308 
1270.474 21.253 0.134 2 0.00 1246.55 0.00 0.00 9407.74 21.253 21.251 21.310 21.302 21.357 
1162.48 21.994 0.134 13 0.00 0.00 0.00 0.00 5650.66 21.994 22.032 22.048 22.046 22.139 
1567.426 32.216 0.135 8 0.00 0.00 0.00 6610.38 0.00 32.216 32.212 32.309 32.286 32.278 
953.3961 20.720 0.135 7 0.00 3349.66 648.74 0.00 0.00 20.720 20.777 20.774 20.799 20.833 
1396 21.859 0.135 2 0.00 6108.72 0.00 35.97 0.00 21.859 21.916 21.913 21.885 21.959 
1311.893 25.277 0.136 20 0.00 2457.36 1890.56 0.00 3237.08 25.277 25.310 25.337 25.414 25.376 
1420.535 19.379 0.135 6 0.00 3209.06 4022.02 0.00 2043.86 19.379 19.406 19.434 19.495 19.512 
1213.392 20.787 0.135 5 0.34 11219.01 1076.95 0.00 0.00 20.787 20.835 20.841 20.862 20.899 
469.3761 29.534 0.135 2 877.89 1046.57 602.64 751.63 701.01 29.534 29.583 29.627 29.604 29.601 
1093.438 32.149 0.134 4 0.00 0.00 0.00 0.00 4529.95 32.149 32.148 32.241 32.225 32.223 
918.6971 21.657 0.134 3 0.00 108.86 0.00 2306.43 0.00 21.657 21.707 21.711 21.679 21.690 
1336.212 20.787 0.135 6 991.67 5476.34 0.00 0.00 0.00 20.787 20.835 20.841 20.862 20.899 
1015.689 21.724 0.135 9 0.00 0.00 0.00 2699.32 0.00 21.724 21.785 21.778 21.742 21.764 
1389.738 20.787 0.135 2 0.00 4862.09 0.00 0.00 0.00 20.787 20.835 20.841 20.862 20.899 
1292.439 29.865 0.131 4 0.00 4707.34 0.00 0.00 0.00 29.865 29.934 29.960 29.931 29.928 
869.8978 21.657 0.134 3 0.00 789.43 520.53 3437.14 0.00 21.657 21.707 21.711 21.679 21.690 
1358.967 21.320 0.135 17 0.00 143.25 0.00 0.00 3030.74 21.320 21.324 21.377 21.364 21.409 
1014.563 21.657 0.134 10 0.00 41.81 276.00 3038.28 0.00 21.657 21.707 21.711 21.679 21.690 
  
960.3939 21.859 0.135 8 0.00 1634.34 0.00 272.02 0.00 21.859 21.916 21.913 21.885 21.959 
1303.59 19.447 0.135 2 0.00 3110.91 0.00 2129.39 0.00 19.447 19.475 19.499 19.563 19.580 
2098.386 23.674 0.133 12 0.00 0.00 0.00 6836.82 3134.27 23.674 23.686 23.725 23.774 23.762 
1163.469 21.724 0.135 10 0.00 0.00 0.00 4314.84 3166.52 21.724 21.785 21.778 21.742 21.764 
867.2157 21.657 0.134 2 0.00 0.00 0.00 2048.30 0.00 21.657 21.707 21.711 21.679 21.690 
962.8974 31.141 0.133 17 0.00 0.00 0.00 1520.01 0.00 31.141 31.188 31.236 31.242 31.245 
820.8829 21.657 0.134 3 0.00 0.00 0.00 1844.70 0.00 21.657 21.707 21.711 21.679 21.690 
1252.014 25.210 0.133 11 0.00 0.00 2977.73 0.00 3220.08 25.210 25.243 25.269 25.349 25.308 
1281.304 20.720 0.135 2 0.00 4682.11 0.00 0.00 0.00 20.720 20.777 20.774 20.799 20.833 
1004.426 21.724 0.135 3 0.00 366.32 0.00 3795.04 0.00 21.724 21.785 21.778 21.742 21.764 
1537.138 28.802 0.131 11 0.00 0.00 0.00 0.00 3765.66 28.802 28.852 28.890 28.881 28.887 
1208.768 7.198 0.133 2 0.00 5013.25 0.00 0.00 0.00 7.198 7.069 7.243 7.267 7.270 
1566.589 20.720 0.135 2 0.00 8497.95 0.00 0.00 0.00 20.720 20.777 20.774 20.799 20.833 
734.0469 30.470 0.202 2 1122.89 1352.85 858.01 0.00 0.00 30.470 30.552 30.566 30.519 30.518 
1313.936 21.320 0.135 20 0.00 0.00 0.00 0.00 2759.23 21.320 21.324 21.377 21.364 21.409 
797.6879 31.409 0.135 6 0.00 1691.69 0.00 0.00 0.00 31.409 31.444 31.504 31.484 31.505 
795.9906 21.724 0.135 4 0.00 0.00 0.00 1473.86 0.00 21.724 21.785 21.778 21.742 21.764 
1468.103 31.341 0.133 2 0.00 8749.77 3230.81 0.00 0.00 31.341 31.380 31.436 31.423 31.440 
811.4185 22.259 0.135 5 0.00 1357.95 0.00 0.00 0.00 22.259 22.264 22.317 22.368 22.377 
1244.863 28.802 0.131 15 0.00 0.00 0.00 626.57 4671.98 28.802 28.852 28.890 28.881 28.887 
1297.119 20.720 0.135 19 0.00 3172.08 0.00 0.00 0.00 20.720 20.777 20.774 20.799 20.833 
1404.932 29.000 0.135 12 0.00 4107.11 0.00 0.00 0.00 29.000 29.039 29.092 29.077 29.078 
1116.605 21.320 0.202 18 0.00 1969.83 0.00 0.00 2538.00 21.320 21.324 21.377 21.364 21.409 
1113.789 28.205 0.131 10 0.00 3877.65 0.00 0.00 0.00 28.205 28.297 28.281 28.292 28.338 
1482.733 32.081 0.134 16 0.00 0.00 0.00 2444.68 3217.17 32.081 32.084 32.174 32.127 32.158 
1272.878 21.859 0.135 6 1780.17 3307.26 0.00 0.00 0.00 21.859 21.916 21.913 21.885 21.959 
1605.481 21.994 0.134 9 0.00 0.00 0.00 0.00 3736.82 21.994 22.032 22.048 22.046 22.139 
1398.653 31.341 0.133 11 0.00 3273.26 1462.20 0.00 0.00 31.341 31.380 31.436 31.423 31.440 
837.5022 21.657 0.134 2 0.00 794.41 0.00 1793.52 235.84 21.657 21.707 21.711 21.679 21.690 
1425.858 21.724 0.135 9 0.00 0.00 2037.33 5685.49 1345.46 21.724 21.785 21.778 21.742 21.764 
1416.292 20.787 0.135 15 0.00 2766.53 1756.61 0.00 0.00 20.787 20.835 20.841 20.862 20.899 
1439.95 22.259 0.135 18 0.00 2273.04 0.00 0.00 0.00 22.259 22.264 22.317 22.368 22.377 
  
1181.466 21.320 0.135 8 0.00 1515.54 0.00 0.00 3898.76 21.320 21.324 21.377 21.364 21.409 
971.3237 21.657 0.134 18 0.00 429.45 0.00 2261.31 0.00 21.657 21.707 21.711 21.679 21.690 
1205.143 21.253 0.134 19 0.00 0.00 0.00 0.00 1736.76 21.253 21.251 21.310 21.302 21.357 
1216.083 28.933 0.133 7 0.00 3036.36 0.00 0.00 0.00 28.933 28.977 29.024 29.011 29.013 
1412.571 29.865 0.131 12 0.00 3345.95 0.00 0.00 0.00 29.865 29.934 29.960 29.931 29.928 
843.2562 21.657 0.134 3 0.00 0.00 0.00 4047.74 795.44 21.657 21.707 21.711 21.679 21.690 
783.9411 21.657 0.134 9 0.00 0.00 0.00 1537.09 0.00 21.657 21.707 21.711 21.679 21.690 
950.2057 21.724 0.135 16 0.00 0.26 0.00 3102.46 0.00 21.724 21.785 21.778 21.742 21.764 
1046.669 22.259 0.135 18 838.82 1664.48 0.00 1063.27 0.00 22.259 22.264 22.317 22.368 22.377 
1192.757 20.787 0.135 17 0.00 3207.40 0.00 0.00 1164.10 20.787 20.835 20.841 20.862 20.899 
1052.436 20.787 0.135 20 808.35 1964.78 0.00 0.00 0.00 20.787 20.835 20.841 20.862 20.899 
996.9377 28.270 0.131 3 0.00 2300.34 0.00 0.00 0.00 28.270 28.358 28.349 28.357 28.399 
1384.957 28.933 0.133 12 0.00 4044.39 0.00 804.70 0.00 28.933 28.977 29.024 29.011 29.013 
1353.284 30.470 0.135 11 0.00 2891.43 0.00 0.00 0.00 30.470 30.552 30.566 30.519 30.518 
1245.936 21.657 0.134 14 0.00 0.00 0.00 2033.72 0.00 21.657 21.707 21.711 21.679 21.690 
1473.342 21.253 0.134 19 0.00 0.00 0.00 0.00 3030.04 21.253 21.251 21.310 21.302 21.357 
1221.121 20.720 0.135 19 0.00 919.51 0.00 0.00 0.00 20.720 20.777 20.774 20.799 20.833 
800.8882 20.787 0.135 12 0.00 1085.61 0.00 0.00 0.00 20.787 20.835 20.841 20.862 20.899 
2005.284 20.720 0.135 9 0.00 4706.10 0.00 0.00 0.00 20.720 20.777 20.774 20.799 20.833 
1714.458 20.720 0.135 10 0.00 3603.94 0.00 0.00 0.00 20.720 20.777 20.774 20.799 20.833 
1236.973 32.283 0.135 3 0.00 3724.24 0.00 0.00 0.00 32.283 32.276 32.376 32.346 32.332 
1513.448 28.270 0.131 10 0.00 3093.99 0.00 0.00 0.00 28.270 28.358 28.349 28.357 28.399 
1304.315 31.341 0.133 14 2065.73 1771.28 0.00 0.00 0.00 31.341 31.380 31.436 31.423 31.440 
971.2511 29.865 0.131 7 0.00 1121.13 0.00 0.00 0.00 29.865 29.934 29.960 29.931 29.928 
997.322 22.259 0.135 3 0.00 1788.54 0.00 0.00 0.00 22.259 22.264 22.317 22.368 22.377 
956.3617 20.787 0.135 5 0.00 2684.78 0.00 0.00 0.00 20.787 20.835 20.841 20.862 20.899 
1316.245 21.724 0.135 11 0.00 0.00 0.00 3012.66 0.00 21.724 21.785 21.778 21.742 21.764 
1375.842 20.720 0.135 17 0.00 2178.76 0.00 0.00 0.00 20.720 20.777 20.774 20.799 20.833 
1779.183 31.409 0.135 9 0.00 2896.74 0.00 0.00 0.00 31.409 31.444 31.504 31.484 31.505 
1438.395 20.720 0.135 9 0.00 3798.72 0.00 0.00 0.00 20.720 20.777 20.774 20.799 20.833 
1220.232 20.787 0.135 4 18.85 2913.12 0.00 0.00 0.00 20.787 20.835 20.841 20.862 20.899 
1305.044 32.216 0.135 13 0.00 2956.20 0.00 0.00 0.00 32.216 32.212 32.309 32.286 32.278 
  
1552.844 31.341 0.133 11 0.00 3823.35 0.00 3083.03 0.00 31.341 31.380 31.436 31.423 31.440 
982.1032 22.259 0.135 3 0.00 4052.23 683.53 0.00 443.16 22.259 22.264 22.317 22.368 22.377 
1169.702 20.720 0.135 15 0.00 2865.93 566.25 0.00 0.00 20.720 20.777 20.774 20.799 20.833 
1094.67 22.191 0.133 2 2011.54 2356.81 24.74 0.00 0.00 22.191 22.205 22.250 22.287 22.317 
1813.41 30.470 0.135 11 0.00 3783.79 0.00 0.00 0.00 30.470 30.552 30.566 30.519 30.518 
1288.052 20.787 0.135 11 0.00 3111.42 0.00 0.00 0.00 20.787 20.835 20.841 20.862 20.899 
1969.687 31.341 0.133 17 0.00 3916.57 0.00 0.00 0.00 31.341 31.380 31.436 31.423 31.440 
1241.583 32.216 0.135 18 0.00 2331.13 0.00 0.00 0.00 32.216 32.212 32.309 32.286 32.278 
1039.69 22.191 0.133 4 375.78 1488.05 0.00 0.00 0.00 22.191 22.205 22.250 22.287 22.317 
1154.465 28.205 0.131 15 0.00 1747.61 0.00 0.00 0.00 28.205 28.297 28.281 28.292 28.338 
1408.574 32.216 0.135 12 2126.45 2655.85 0.00 0.00 0.00 32.216 32.212 32.309 32.286 32.278 
866.069 21.657 0.134 2 0.00 91.36 0.00 2506.26 0.00 21.657 21.707 21.711 21.679 21.690 
1715.638 32.216 0.135 13 0.00 3901.60 0.00 0.00 0.00 32.216 32.212 32.309 32.286 32.278 
1215.061 22.191 0.133 11 0.00 2344.37 0.00 0.00 0.00 22.191 22.205 22.250 22.287 22.317 
1244.685 32.216 0.135 2 0.00 1945.92 0.00 0.00 0.00 32.216 32.212 32.309 32.286 32.278 
1137.733 22.259 0.135 11 0.00 2441.72 0.00 0.00 0.00 22.259 22.264 22.317 22.368 22.377 
1299.908 21.320 0.135 12 0.00 0.00 0.00 1925.55 4155.67 21.320 21.324 21.377 21.364 21.409 
951.8954 21.657 0.134 20 0.00 0.00 0.00 1633.00 0.00 21.657 21.707 21.711 21.679 21.690 
1463.775 32.216 0.135 12 0.00 3035.86 0.00 0.00 0.00 32.216 32.212 32.309 32.286 32.278 
1189.711 32.283 0.135 9 0.00 3088.48 620.97 0.00 159.05 32.283 32.276 32.376 32.346 32.332 
1302.26 29.865 0.131 17 0.00 1680.23 0.00 0.00 0.00 29.865 29.934 29.960 29.931 29.928 
1505.809 20.720 0.135 15 2445.37 4449.98 6692.08 0.00 0.00 20.720 20.777 20.774 20.799 20.833 
1212.033 28.205 0.131 20 0.00 1795.79 0.00 0.00 0.00 28.205 28.297 28.281 28.292 28.338 
1557.637 28.205 0.131 13 0.00 2809.00 0.00 0.00 0.00 28.205 28.297 28.281 28.292 28.338 
1206.437 20.720 0.135 15 0.00 1825.34 0.00 0.00 0.00 20.720 20.777 20.774 20.799 20.833 
1123.427 22.259 0.135 3 1337.64 2219.22 0.00 0.00 1127.07 22.259 22.264 22.317 22.368 22.377 
1379.446 22.663 0.135 14 0.00 0.00 0.00 0.00 2077.69 22.663 22.671 22.722 22.739 22.734 
579.4346 32.216 0.135 7 0.00 366.89 0.00 0.00 0.00 32.216 32.212 32.309 32.286 32.278 
1030.393 29.930 0.133 12 0.00 1355.15 0.00 1123.36 0.00 29.930 29.995 30.028 29.996 29.994 
1432.695 32.216 0.135 14 0.00 1542.38 0.00 0.00 0.00 32.216 32.212 32.309 32.286 32.278 
1378.455 28.270 0.131 18 0.00 981.97 0.00 0.00 0.00 28.270 28.358 28.349 28.357 28.399 
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